US20150098997A1 - Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions - Google Patents

Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions Download PDF

Info

Publication number
US20150098997A1
US20150098997A1 US14/505,933 US201414505933A US2015098997A1 US 20150098997 A1 US20150098997 A1 US 20150098997A1 US 201414505933 A US201414505933 A US 201414505933A US 2015098997 A1 US2015098997 A1 US 2015098997A1
Authority
US
United States
Prior art keywords
dexmedetomidine
subject
transdermal delivery
delivery device
transdermal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/505,933
Other languages
English (en)
Inventor
Adchara Pongpeerapat
Amit Jain
Bret Berner
Jianye Wen
Jutaro Shudo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teikoku Pharma USA Inc
Original Assignee
Teikoku Pharma USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teikoku Pharma USA Inc filed Critical Teikoku Pharma USA Inc
Priority to US14/505,933 priority Critical patent/US20150098997A1/en
Assigned to TEIKOKU PHARMA USA, INC. reassignment TEIKOKU PHARMA USA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BERNER, BRET, SHUDO, JUTARO, WEN, JIANYE, JAIN, AMIT, PONGPEERAPAT, ADCHARA
Publication of US20150098997A1 publication Critical patent/US20150098997A1/en
Priority to US16/587,995 priority patent/US10874642B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Definitions

  • Attention Deficit Hyperactivity Disorder is a neurobehavioral disorder characterized primarily by inattention, easy distractibility, disorganization, procrastination, and forgetfulness. Attention Deficit Hyperactivity Disorder is a condition that typically manifests in children in the preschool and early school years making it difficult for these children to control their behavior or pay attention. It is estimated that between 3 and 5 percent of children have attention deficit hyperactivity disorder (ADHD), or approximately 2 million children in the United States. It is believed that in a classroom of 24 to 30 children, there is likely that at least one child will have ADHD. ADHD is characterized by inattention, hyperactivity, and impulsivity. The America Psychiatric Association in the Diagnostic and Statistical Manual of Mental Disorders have established three sub-types of ADHD.
  • ADHD Predominantly Inattentive Type presents with symptoms including being easily distracted, forgetful, daydreaming, disorganization, poor concentration, and difficulty completing tasks.
  • ADHD, Predominantly Hyperactive-Impulsive Type presents with excessive fidgetiness and restlessness, hyperactivity, difficulty waiting and remaining seated, immature behavior; destructive behaviors may also be present.
  • ADHD, Combined Type is a combination of ADHD Predominantly Inattentive Type and ADHD, Predominantly Hyperactive-Impulsive Type.
  • Anxiety disorder is a psychiatric disorder characterized by excessive rumination, worrying, uneasiness, apprehension and fear about future uncertainties either based on real or imagined events, which may affect both physical and psychological health.
  • the American Psychiatric Association has established that term anxiety includes four aspects or experiences that an individual with anxiety disorder may have: mental apprehension, physical tension, physical symptoms and dissociative anxiety.
  • Insomnia is a sleep disorder in which there is an inability to fall asleep or to stay asleep as long as desired. Insomnia is often attributed both as a sign and as a symptom of accompanying sleep, medical, and/or psychiatric disorders characterized by a persistent difficulty falling asleep, staying asleep or suffering from sleep of poor quality. Insomnia is typically followed by functional impairment while awake. Insomnia can occur at any age, but it is particularly common in the elderly. Insomnia can be persistent for a short duration (e.g., lasting less than three weeks) or for a long duration (e.g., lasting greater than 3-4 weeks), which often leads to memory problems, depression, irritability and an increased risk of heart disease and automobile related accidents.
  • a short duration e.g., lasting less than three weeks
  • a long duration e.g., lasting greater than 3-4 weeks
  • Dexmedetomidine is the S-enantiomer of medetomidine and is an agonist of ⁇ 2 -adrenergic receptors that is used as a sedative medication in intensive care units and by anesthetists for intubated and nonintubated patients requiring sedation for surgery or short term procedures.
  • the ⁇ 2 -adrenergic receptor is a G-protein coupled receptor associated with the G i heterotrimeric G-protein that includes three highly homologous subtypes, including ⁇ ta , ⁇ 2b and ⁇ 2c -adrenergic receptors. Agonists of the a 2 -adrenergic receptor are implicated in sedation, muscle relaxation and analgesia through effects on the central nervous system.
  • Dexmedetomidine is used in clinical settings as a sedative through parenteral, intravenous and oral administration and thus, requires close supervision by a health care professional in a hospital setting.
  • Dexmedetomidine is currently employed for sedation of intubated or mechanically ventilated subjects in an in-clinic (e.g., hospital) setting as well as for the sedation of non-intubated subjects as a part of monitored anesthesia during surgery, radiography or diagnostic procedures.
  • Dexmedetomidine is also approved for continuous intravenous infusion in non-intubated subjects since it does not adversely affect breathing.
  • aspects of the invention include methods of treating ADHD, anxiety or insomnia by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver an amount of dexmedetomidine to a subject diagnosed as having ADHD, anxiety or insomnia.
  • a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine sufficient to treat ADHD, anxiety or insomnia in the subject.
  • transdermal delivery devices configured to deliver an amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices.
  • FIG. 1 shows an example of a plot of average dexmedetomidine flux as a function of transdermal delivery device application time for a dexmedetomidine transdermal composition with polyisobutylene/polybutene and crosslinked polyvinylpyrrolidone adhesive according to one embodiment.
  • FIG. 2 shows an example of cumulative dexmedetomidine delivered amount with time according to one embodiment.
  • FIG. 2 shows an example of a plot of average dexmedetomidine flux as a function of transdermal delivery device application time for a dexmedetomidine transdermal composition having a non-functionalized acrylate adhesive according to one embodiment.
  • FIG. 2 shows an example of dexmedetomidine utilization with time according to one embodiment.
  • FIG. 3 shows an example of a plot of average dexmedetomidine flux as a function of transdermal delivery device application time for a dexmedetomidine transdermal composition having a non-functionalized acrylate adhesive according to one embodiment.
  • FIG. 4 shows an example of a plot of average dexmedetomidine flux as a function of transdermal delivery device application time for a dexmedetomidine transdermal composition having a hydroxyl functionalized acrylate adhesive containing vinyl acetate according to one embodiment.
  • FIG. 5 shows an example of a plot of average dexmedetomidine flux as a function of transdermal delivery device application time for a dexmedetomidine transdermal composition having a hydroxyl functionalized acrylate adhesive according to another embodiment.
  • FIG. 6 shows an example of a plot of average dexmedetomidine flux as a function of transdermal delivery device application time for a dexmedetomidine transdermal composition having hydroxyl functionalized acrylate adhesive and a hydroxyl functionalized acrylate adhesive containing vinyl acetate according to another embodiment.
  • FIGS. 7A-7B shows an example of a plot of average dexmedetomidine flux as a function of transdermal delivery device application time for dexmedetomidine transdermal compositions having a non-functionalized acrylate adhesive, a hydroxyl functionalized acrylate adhesive and a hydroxyl functionalized acrylate adhesive containing vinylacetate according to one embodiment.
  • FIG. 8 shows an example of a plot of average dexmedetomidine flux as a function of transdermal delivery device application time for a dexmedetomidine transdermal composition having a carboxylic acid functionalized acrylate adhesive according to another embodiment.
  • FIG. 9 shows an example of a plot of average dexmedetomidine flux as a function of transdermal delivery device application time for a dexmedetomidine transdermal composition having acrylic adhesive with carboxyl group and hydroxyl group as the functional group containing vinyl acetate according to another embodiment.
  • FIG. 10 shows an example of a plot of average dexmedetomidine flux as a function of transdermal delivery device application time for a dexmedetomidine transdermal composition having a polyisobutylene/polybutene adhesive with a carboxylic acid functionalized acrylate adhesive according to one embodiment.
  • FIG. 11 shows an example of a plot of average dexmedetomidine flux as a function of transdermal delivery device application time for a dexmedetomidine transdermal composition having a polyisobutylene/polybutene adhesive with the solubility enhancer levulinic acid according to one embodiment.
  • FIG. 12 shows an example of a plot of average dexmedetomidine flux as a function of transdermal delivery device application time for a dexmedetomidine transdermal composition having a polyisobutylene/polybutene adhesive with the solubility enhancer lauryl lactate according to one embodiment.
  • FIG. 13 shows an example of a plot of average dexmedetomidine flux as a function of transdermal delivery device application time for a dexmedetomidine transdermal composition having a polyisobutylene/polybutene adhesive with the solubility enhancer propylene glycolmonolaurate according to one embodiment.
  • FIG. 14A shows an example of a plot of average dexmedetomidine flux as a function of transdermal delivery device application time for a dexmedetomidine transdermal composition having a hydroxyl functionalized acrylate adhesive containing vinyl acetate with levulinic acid according to one embodiment.
  • FIG. 14B shows an example of a plot of average dexmedetomidine flux as a function of transdermal delivery device application time for a dexmedetomidine transdermal composition having a hydroxyl functionalized acrylate adhesive containing vinyl acetate with polyvinylpyrrolidone according to one embodiment.
  • FIG. 14C shows an example of a plot of average dexmedetomidine flux as a function of transdermal delivery device application time for a dexmedetomidine transdermal composition having a hydroxyl functionalized acrylate adhesive containing vinyl acetate with a carboxylic acid functionalized acrylate adhesive according to one embodiment.
  • FIG. 15 shows an example of a plot of average dexmedetomidine flux as a function of transdermal delivery device application time for a dexmedetomidine transdermal composition having acrylate pressure sensitive adhesive in the absence and presence of levulinic acid, oleic acid or a carboxylic acid functionalized acrylate adhesive according to one embodiment.
  • FIG. 16 shows an example of a plot of average dexmedetomidine flux as a function of transdermal delivery device application time for a dexmedetomidine transdermal composition having a hydroxyl functionalized acrylate adhesive containing vinyl acetate with a carboxylic acid functionalized acrylate adhesive according to another embodiment.
  • FIG. 17 shows an example of a plot of average dexmedetomidine flux as a function of transdermal delivery device application time for a dexmedetomidine transdermal composition having a hydroxyl functionalized acrylate adhesive containing vinyl acetate with oleic acid or a carboxylic acid functionalized acrylate adhesive according to another embodiment.
  • FIG. 18 shows an example of a plot of average dexmedetomidine flux as a function of transdermal delivery device application time for a dexmedetomidine transdermal composition having a hydroxyl functionalized acrylate adhesive containing vinyl acetate with solubility enhancers such as carboxylic acid functionalized acrylate adhesives, lauryl lactate or oleic acid according to another embodiment.
  • FIG. 19 shows the average dexmedetomidine in-vitro skin flux with respect to time from various formulations.
  • FIGS. 20 and 21 show the flux on two different skin samples from various formulations.
  • aspects of the invention include methods of treating ADHD, anxiety or insomnia by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver an amount of dexmedetomidine to a subject diagnosed as having ADHD, anxiety or insomnia.
  • a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine sufficient to treat ADHD, anxiety or insomnia in the subject.
  • transdermal delivery devices configured to deliver an amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices.
  • transdermal delivery device having a dexmedetomidine composition and maintaining the transdermal delivery device in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine to treat ADHD, anxiety or insomnia in the subject are first reviewed in greater detail.
  • transdermal delivery devices suitable for practicing the subject methods are described. Kits that include transdermal delivery devices of interest are then reviewed.
  • ADHD Attention Deficit Hyperactivity Disorder
  • Anxiety or Insomnia with Dexmedetomidine Transdermal Delivery Devices
  • aspects of the invention include methods of treating ADHD, anxiety or insomnia by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver an amount of dexmedetomidine to a subject diagnosed as having ADHD, anxiety or insomnia.
  • a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine sufficient to treat ADHD, anxiety or insomnia in the subject.
  • the term “transdermal” is used in its conventional sense to refer to the route of administration where an active agent (i.e., drug) is delivered across the skin (e.g., topical administration) or mucous membrane for systemic distribution.
  • transdermal dexmedetomidine compositions as described herein include compositions which are delivered to the subject through one or more of the subcutis, dermis and epidermis, including the stratum corneum, stratum germinativum, stratum spinosum and stratum basale.
  • extended transdermal delivery devices containing a transdermal dexmedetomidine composition may be applied at any convenient location, such as for example, the arms, legs, buttocks, abdomen, back, neck, scrotum, vagina, face, behind the ear, buccally as well as sublingually.
  • the term “subject” is meant the person or organism to which the transdermal composition is applied and maintained in contact.
  • subjects of the invention may include but are not limited to mammals, e.g., humans and other primates, such as chimpanzees and other apes and monkey species; and the like, where in certain embodiments the subject are humans.
  • the term subject is also meant to include a person or organism of any age, weight or other physical characteristic, where the subjects may be an adult, a child, an infant or a newborn.
  • Methods for treating ADHD or an associated disorder, anxiety or insomnia includes treatment of a juvenile subject.
  • the subject may be a child under the age of 8 years, such as a child under the age of 5 years.
  • Transdermal administration of dexmedetomidine may be passive or active.
  • Passive transport is meant that the dexmedetomidine composition is delivered across the skin or mucous membrane in the absence of applied energy (e.g., rubbing or heat) and is primarily dependent on the permeability of the barrier (e.g., skin or mucous membrane) and by entropy of delivery.
  • transdermal administration may also include active transport of the dexmedetomidine composition across the skin or mucous membrane.
  • Active transport can be any convenient protocol sufficient to transport the composition through the skin or mucous membrane in conjunction with applied energy and may include, but is not limited to microneedle delivery, facilitated diffusion, electrochemically-produced gradients, iontophoretic systems, among other protocols.
  • a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine to treat ADHD, anxiety or insomnia in the subject.
  • ADHD refers to the psychiatric disorder or neurobehavioral disorder characterized by significant difficulties either of inattention or hyperactivity and impulsiveness or a combination thereof.
  • ADHD as used herein includes the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) designation of the three subtypes of the disorder which include being predominantly inattentive (ADHD-PI or ADHD-I), predominantly hyperactive-impulsive (ADHD-HI or ADHD-H), or the two combined (ADHD-C).
  • disorders associated with ADHD may also be treated by the subject methods, the associated disorders including but not limited to restless legs syndrome, oppositional defiant and conduct disorder, bipolar disorder, major depressive disorder, anxiety disorders, obsessive compulsive disorder as well as sleep disorders including insomnia, obstructive sleep apnea syndrome.
  • anxiety disorder is used herein in its conventional sense to refer to the psychiatric disorder characterized by excessive rumination, worrying, uneasiness, apprehension and fear about future uncertainties either based on real or imagined events, which may affect both physical and psychological health (e.g., in accordance with the American Psychiatric Association establishment of anxiety which includes mental apprehension, physical tension, physical symptoms and dissociative anxiety) and may include the anxiety disorders generalized anxiety disorder (GAD), panic disorder, phobias and separation anxiety disorder.
  • GAD generalized anxiety disorder
  • the term “insomnia” is used herein in its conventional sense to refer the disorder characterized by the inability to fall asleep or to stay asleep as long as desired. Insomnia may include any of several sleep, medical, and psychiatric disorders which is characterized by a persistent difficulty falling asleep, staying asleep or suffering from sleep of poor quality.
  • a subject is diagnosed as having one or more of ADHD, anxiety and insomnia.
  • a subject may be diagnosed as having ADHD, anxiety or insomnia by a qualified health care professional using any suitable protocol, such as for example protocols set forth by the American Psychiatric Association.
  • ADHD, anxiety and insomnia are diagnosed according to criteria provided by the Diagnostic and Statistical Manual of Mental Disorders (e.g., DSM-V, released May 2013).
  • a subject is diagnosed as having one of the three subtypes of ADHD designated by the Diagnostic and Statistical Manual of Mental Disorders (e.g., DSM-V, released May 2013): predominantly inattentive (ADHD-PI or ADHD-I), predominantly hyperactive-impulsive (ADHD-HI or ADHD-H), or the two combined (ADHD-C).
  • disorders associated with ADHD may also be diagnosed in the subject, the associated disorders including but not limited to restless legs syndrome, oppositional defiant and conduct disorder, bipolar disorder, major depressive disorder, anxiety disorders, obsessive compulsive disorder as well as sleep disorders including insomnia, obstructive sleep apnea syndrome.
  • subjects are diagnosed as having insomnia according to the Epworth Sleepiness Scale, the Sleep Disorders Questionnaire, the Pittsburgh Sleep Quality Index, the Insomnia Severity Index, the use of sleep diary to track sleeping patterns, a polysomnogram to measure activity during sleep, actigraphy for assess sleep-wake patterns, among other convenient protocols for diagnosing insomnia.
  • a subject is diagnosed as having anxiety according to the Diagnostic and Statistical Manual of Mental Disorders (e.g., DSM-V, released May 2013) such as according to diagnosis criteria for evaluating generalized anxiety disorder, panic disorder, post-traumatic stress disorder, obsessive compulsive disorder and separation anxiety disorder in children.
  • DSM-V Diagnostic and Statistical Manual of Mental Disorders
  • methods further include diagnosing a subject as having one or more of ADHD, anxiety and insomnia.
  • diagnosing ADHD, anxiety and insomnia may include conducting a medical examination such as to rule out other causes of observable symptoms.
  • diagnosing ADHD may include gathering information from the subject such through an interview, questionnaire or by review of previous medical conditions, diaries of sleep, nighttime activity, family history and behavioral records. This may include gathering information may include observing symptoms of inattention in the subject, hyperactivity, impulsivity or restlessness.
  • Diagnosing insomnia may include medical examination, interview, questionnaire and sleep tests according to the Epworth Sleepiness Scale, the Sleep Disorders Questionnaire, the Pittsburgh Sleep Quality Index, the Insomnia Severity Index as well as the use of sleep diary to track sleeping patterns, a polysomnogram to measure activity during sleep, actigraphy for assess sleep-wake patterns, among other convenient protocols for diagnosing insomnia.
  • Diagnosing anxiety may include gathering information from the subject such through an interview, questionnaire or by review of previous medical conditions, family history and behavioral records.
  • a subject diagnosed as having anxiety may be further evaluate to determine if the subject has one or more of generalized anxiety disorder, panic disorder, post-traumatic stress disorder or obsessive compulsive disorder. Where the subject is a child, diagnosing may include determining that the subject has separation anxiety disorder.
  • methods include applying to a skin surface of a subject diagnosed as having ADHD, anxiety or insomnia a transdermal delivery device having a dexmedetomidine composition that contains dexmedetomidine and a pressure sensitive adhesive and maintaining the transdermal delivery device in contact with the subject in a manner sufficient to deliver dexmedetomidine over a period of time to treat ADHD, anxiety or insomnia in the subject.
  • treating or “treatment” is meant at least a suppression or amelioration of the symptoms associated with the condition affecting the subject, where suppression and amelioration are used in a broad sense to refer to at least a reduction in the magnitude of a parameter, e.g., symptom, associated with ADHD, anxiety or insomnia.
  • treatment of ADHD, anxiety or insomnia includes situations where ADHD, anxiety or insomnia is completely inhibited, e.g., prevented from happening, or stopped, e.g., terminated, such that the subject no longer experiences ADHD, anxiety or insomnia.
  • methods include applying a transdermal delivery device having a dexmedetomidine composition to a subject and maintaining the transdermal delivery device in contact with the subject in a manner to deliver an amount of dexmedetomidine sufficient to treat ADHD, anxiety or insomnia in the subject.
  • methods include maintaining the transdermal delivery device in contact with the subject in a manner sufficient to deliver a sedative amount of dexmedetomidine.
  • sedative is meant that the dexmedetomidine composition is formulated to deliver an amount of dexmedetomidine to the subject which causes at least partial sedation.
  • methods include delivering an amount of dexmedetomidine to the subject such that the subject is characterized as being in a state where the subject can exhibit brisk response to light glabellar tap or loud auditory stimulus.
  • methods include delivering an amount of dexmedetomidine to the subject such that the subject is characterized as being in a state where the subject exhibits a sluggish response to light glabellar tap or loud auditory stimulus.
  • dexmedetomidine compositions of interest are formulated to deliver an amount of dexmedetomidine which is fully sedative and the subject is characterized as being in a state where the subject exhibits no response to touch or auditory stimulus.
  • Suitable protocols for determining level of sedation may include but are not limited to the Ramsay Sedation Scale, the Vancouver Sedative Recovery Scale, the Glasgow Coma Scale modified by Cook and Palma, the Comfort Scale, the New Sheffield Sedation Scale, the Sedation-Agitation Scale, and the Motor Activity Assessment Scale, among other convenient protocols for determining the level of sedation.
  • methods may further include evaluating the level of sedation of the subject to determine whether any reduction in responsiveness or cognitive or motor activity has resulted from administration of a transdermal delivery device.
  • the level of sedation may be evaluated by any convenient protocol, such as with those mentioned above.
  • the level of sedation is evaluated using the Ramsey Sedation Scale, (as disclosed in Ramsay, et al. Controlled sedation with alphaxalone-alphadolone, British Med Journal 1974; 2:656-659, the disclosure of which is herein incorporated by reference).
  • each subject may be evaluated by a qualified health care professional and assigned a score for the level of sedation according to the Ramsey Sedation Scale, summarized below.
  • Ramsay Sedation Scale Score Description of Responsiveness, Cognitive and Motor Activity 1 Patient is anxious and agitated or restless, or both 2 Patient is co-operative, oriented, and tranquil 3 Patient responds to commands only 4 Patient exhibits brisk response to light glabellar tap or loud auditory stimulus 5 Patient exhibits a sluggish response to light glabellar tap or loud auditory stimulus 6 Patient exhibits no response
  • methods may include delivering an amount of dexmedetomidine to the subject in manner sufficient to maintain a Ramsay score of between 2 and 5 in the subject, such as between 3 and 5 and including a Ramsay score of between 4 and 5.
  • the subject throughout administration of the dexmedetomidine transdermal composition, the subject exhibits brisk response to light glabellar tap or loud auditory stimulus. In other instances, throughout administration of the dexmedetomidine transdermal composition, the subject exhibits a sluggish response to light glabellar tap or loud auditory stimulus. In yet other instances, throughout administration of the dexmedetomidine transdermal composition, the subject is fully sedated and exhibits no response to touch or auditory stimulus.
  • the level of sedation of a subject may be evaluated at any time during the methods.
  • the level of sedation is evaluated while maintaining the extended transdermal delivery device in contact with the subject at regular intervals, e.g., every 0.25 hours, every 0.5 hours, every 1 hour, every 2 hours, every 4 hours or some other interval.
  • the level of sedation may be evaluated while maintaining the transdermal delivery device in contact with the subject, such as 15 minutes after applying the transdermal delivery device to the subject, 30 minutes after applying the transdermal delivery device, 1 hour after applying the transdermal delivery device, 2 hours after applying the transdermal delivery device, 4 hours after applying the transdermal delivery device including 8 hours after applying the transdermal delivery device.
  • the level of sedation of the subject may be evaluated one or more times during a dosage interval, such as 2 or more times, such as 3 or more times, including 5 or more times before, during or after a dosage interval.
  • An upper limit for the number of times the subject may be evaluated during a dosage interval is, in some instances, 10 times or fewer, such as 7 times or fewer, such as 5 times or fewer, such as 3 times or fewer and including 2 times or fewer.
  • the number of times the subject may be evaluated during a dosage interval ranges such as from 2 times to 10 times, such as from 3 times to 9 times, such as from 4 times to 8 times and including from 5 times to 7 times.
  • sedation level may be monitored throughout the entire time the transdermal delivery device is maintained in contact with the subject, such by heart rate monitors, breathing monitors or by visual observation, including with the aid of a video monitor.
  • treatment of ADHD, anxiety or insomnia may include one or more dosage intervals.
  • Dosage intervals may last about 2 hours or longer, such as 3 hours or longer, such as 4 hours or longer, such as 6 hours or longer, such as 8 hours or longer, such as 12 hours or longer and including 16 hours or longer.
  • Upper limits for dosage intervals are, in some instances 24 hours or shorter, such as 16 hours or shorter, such as 12 hours or shorter, such as 8 hours or shorter and including 4 hours or shorter.
  • dosage intervals range from 4 hours to 24 hours, such as from 6 hours to 24 hours, such as from 8 hours to 14 hours and including from 12 hours to 16 hours.
  • dosage intervals may be overnight dosage intervals where the dosage interval begins prior to when the subject sleeps and concludes with the waking of the subject.
  • duration of dosage intervals and treatment protocols may vary, as described in greater detail below.
  • at the beginning of the dosage interval the subject being treated is in a non-sedated state and is awake, alert, oriented, coherent and capable of responding to oral or written commands including questions or requests. Delivery of dexmedetomidine to the subject according to certain methods results in the partial or fully sedation of the subject.
  • sustained release transdermal administration of the dexmedetomidine composition includes multi-day delivery of a therapeutically effective amount of the dexmedetomidine active agent that is applied to the skin of a subject.
  • multi-day delivery is meant that the transdermal composition is formulated to provide a therapeutically effective amount to a subject when the transdermal delivery device is applied to the skin of a subject for a period of time that is 1 day or longer, such as 2 days or longer, such as 4 days or longer, such as 7 days or longer, such as 14 days and including 30 days or longer.
  • transdermal delivery devices provide a therapeutically effective amount of dexmedetomidine to a subject for a period of 10 days or longer.
  • an upper limit period of time is, in some instances, 30 days or shorter, such as 28 days or shorter, such as 21 days or shorter, such as 14 days or shorter, such as 7 days or shorter and including 3 days or shorter.
  • multi-day transdermal delivery ranges such as from 2 days to 30 days, such as from 3 days to 28 days, such as from 4 days to 21 days, such as from 5 days to 14 days and including from 6 days to 10 days.
  • treatment protocol refers to one or more sequential dosage intervals sufficient to produce the desired therapeutic effect of transdermal dexmedetomidine composition.
  • protocols may include multiple dosage intervals.
  • multiple dosage intervals is meant more than one transdermal delivery device is applied and maintained in contact with the subject in a sequential manner. As such, a transdermal delivery device is removed from contact with the subject and a new transdermal delivery device is reapplied to the subject.
  • treatment regimens may include two or more dosage intervals, such as three or more dosage intervals, such as four or more dosage intervals, such as five or more dosage intervals, including ten or more dosage intervals.
  • the duration between dosage intervals in a multiple dosage interval treatment protocol may vary, depending on the physiology of the subject or by the treatment protocol as determined by a health care professional.
  • the duration between dosage intervals in a multiple dosage treatment protocol may be predetermined and follow at regular intervals.
  • the time between dosage intervals may vary and may be 1 day or longer, such as 2 days or longer, such as 3 days or longer, such as 4 days or longer, such as 5 days or longer, such as 6 days or longer, such as 7 days or longer, such as 10 days or longer, including 30 days or longer.
  • An upper limit period of time between dosage intervals is, in some instances, 30 days or shorter, such as 28 days or shorter, such as 21 days or shorter, such as 14 days or shorter, such as 7 days or shorter and including 3 days or shorter.
  • the time between dosage intervals ranges such as from 2 days to 30 days, such as from 3 days to 28 days, such as from 4 days to 21 days, such as from 5 days to 14 days and including from 6 days to 10 days.
  • the duration between dosage intervals may depend on the plasma concentration of dexmedetomidine during the time the transdermal delivery device is not in contact with the subject between dosage intervals.
  • a subsequent dosage interval may commence when the plasma concentration of dexmedetomidine reaches below a particular threshold.
  • Methods for treating ADHD, anxiety and insomnia in a subject may include applying a transdermal delivery device containing a dexmedetomidine composition and maintaining the transdermal delivery device in contact with the subject in a manner sufficient to deliver dexmedetomidine to a subject at a rate which averages from 1 ⁇ g/hour to 10 ⁇ g/hour over the course of the dosage interval (e.g., a 8 hour dosage interval), such as from 1.5 ⁇ g/hour to 9.5 ⁇ g/hour, such as from 2 ⁇ g/hour to 9 ⁇ g/hour, such as from 2.5 ⁇ g/hour to 8.5 ⁇ g/hour, such as from 3 ⁇ g/hour to 8 ⁇ g/hour and including from 3.5 ⁇ g/hour to 7.5 ⁇ g/hour over the course of the dosage interval.
  • a rate which averages from 1 ⁇ g/hour to 10 ⁇ g/hour over the course of the dosage interval e.g., a 8 hour dosage interval
  • methods include maintaining the transdermal delivery device in contact with the subject in a manner sufficient to provide a peak rate of dexmedetomidine delivery at specific times during treatment.
  • methods may include applying a transdermal delivery device containing a dexmedetomidine composition and maintaining the transdermal delivery device in contact with the subject in a manner sufficient to achieve a peak rate of dexmedetomidine delivery to the subject at about 0.5 hours or later after applying the transdermal delivery device to the subject, such as at about 1 hour or later, such as at about 1.5 hours or later, such as at about 2 hours or later, such as at about 2.5 hours or later, such as at about 3 hours or later, such as at about 3.5 hours or later and including maintaining the transdermal delivery device in contact with the subject in a manner sufficient to achieve a peak rate of dexmedetomidine delivery to the subject at about 4 hours or later after applying the transdermal delivery device to the subject.
  • the method include applying a transdermal delivery device containing a dexmedetomidine composition and maintaining the transdermal delivery device in contact with the subject in a manner sufficient to achieve a peak rate of dexmedetomidine delivery to the subject at from 0.5 hours to 4 hours after applying the transdermal delivery device to the subject, such as from about 0.75 hours to 3.75 hours, such as from about 1 hour to about 3.5 hours, such as from about 1.25 hours to about 3.25 hours and including as from about 1.5 hours to about 3 hours after applying the transdermal delivery device to the subject.
  • a peak concentration of dexmedetomidine delivery to the subject is achieved at about 3 hours after applying the transdermal delivery device to the subject. In other embodiments, a peak concentration of dexmedetomidine delivery to the subject is achieved at about 4 hours after applying the transdermal delivery device to the subject.
  • the peak rate of delivery may vary depending on the physiology of the subject and desired treatment protocol and may be 0.1 ⁇ g/cm 2 /hr or greater, such as 0.2 ⁇ g/cm 2 /hr or greater, such as 0.3 ⁇ g/cm 2 /hr or greater, such as 0.5 ⁇ g/cm 2 /hr, such as 0.9 ⁇ g/cm 2 /hr, such as 1.5 ⁇ g/cm 2 /hr or greater, such as 2.5 ⁇ g/cm 2 /hr or greater, such as 1.75 ⁇ g/cm 2 /hr or greater and including 4.5 ⁇ g/cm 2 /hr or greater.
  • an upper limit is, in some instances, 10 ⁇ g/cm 2 /hr or less, such as 9 ⁇ g/cm 2 /hr or less, such as 8 ⁇ g/cm 2 /hr or less, such as 7 ⁇ g/cm 2 /hr or less, 6 ⁇ g/cm 2 /hr or less, such as 5 ⁇ g/cm 2 /hr or less and including 2 ⁇ g/cm 2 /hr or less.
  • the peak flux of transdermal dexmedetomidine delivery ranges such as from 0.5 ⁇ g/cm 2 /hr to 10 ⁇ g/cm 2 /hr, such as from 1 ⁇ g/cm 2 /hr to 9 ⁇ g/cm 2 /hr and including from 2 ⁇ g/cm 2 /hr to 8 ⁇ g/cm 2 /hr.
  • Methods according to certain embodiments may include applying to the subject a transdermal delivery device containing a dexmedetomidine composition and maintaining the transdermal dexmedetomidine composition in contact with the subject in a manner sufficient to maintain a transdermal dexmedetomidine flux which is within 30% or more of the peak transdermal dexmedetomidine flux after reaching the peak transdermal flux.
  • the transdermal delivery device is configured to maintain a flux of dexmedetomidine to the subject that is at least 30% of peak flux during the course of any given dosage interval, such as at least 35%, such as at least 40% and including at least 50% of peak flux during the course of any given dosage interval.
  • a flux of dexmedetomidine to the subject that is at least 30% of peak flux during the course of any given dosage interval, such as at least 35%, such as at least 40% and including at least 50% of peak flux during the course of any given dosage interval.
  • the transdermal flux of dexmedetomidine to the subject does not fall below 30% or more of the peak flux at any time during the dosage interval.
  • the transdermal dexmedetomidine composition may be maintained in contact with the subject in a manner sufficient to maintain the transdermal dexmedetomidine flux which is within 80% or more of peak transdermal dexmedetomidine flux, such as within 85% or more, such as within 90% or more, such as within 95% and including within 99% of peak transdermal dexmedetomidine flux after reaching peak transdermal flux.
  • the transdermal dexmedetomidine flux does not decrease at all after reaching peak flux and maintains a rate of 100% of peak dexmedetomidine flux from the moment it reaches peak flux until the end of a given dosage interval.
  • methods include determining the transdermal dexmedetomidine flux.
  • the transdermal dexmedetomidine flux may be determined using any convenient protocol, such for example by protocols employing human cadaver skin with epidermal layers (stratum corneum and epidermis) in a Franz cell having donor and receptor sides clamped together and receptor solution containing phosphate buffer.
  • the flux of the dexmedetomidine can be determined by the equation:
  • Skin flux is the change in cumulative amount of drug entering the body across the skin or mucous membrane with respect to time.
  • the amount of permeated dexmedetomidine can further be characterized by liquid chromatography.
  • the transdermal dexmedetomidine flux may be determined at any time during methods of the invention. In some embodiments, the transdermal dexmedetomidine flux may be monitored throughout the entire time the transdermal dexmedetomidine composition is maintained in contact with the permeation barrier (e.g., human cadaver skin), such by real-time data collection. In other instances, the transdermal dexmedetomidine flux is monitored by collecting data at regular intervals, e.g., collecting data every 0.25 hours, every 0.5 hours, every 1 hour and including every 2 hours or some other interval.
  • the transdermal dexmedetomidine flux is monitored by collecting data according to a particular time schedule.
  • the transdermal dexmedetomidine flux may be determined 15 minutes after applying the transdermal delivery device, 30 minutes after applying the transdermal delivery device, 1 hour after applying the transdermal delivery device, 2 hours after applying the transdermal delivery device and including 3 hours after applying the transdermal delivery device.
  • the transdermal dexmedetomidine flux may be determined one or more times at any given measurement period, such as 2 or more times, such as 3 or more times, including 5 or more times at each measurement period.
  • An upper limit for the number of times the transdermal dexmedetomidine flux is determined is, in some instances, 10 times or fewer, such as 7 times or fewer, such as 5 times or fewer, such as 3 times or fewer and including 2 times or fewer.
  • the number of times the transdermal dexmedetomidine flux is determined ranges such as from 2 times to 10 times, such as from 3 times to 9 times, such as from 4 times to 8 times and including from 5 times to 7 times.
  • the transdermal composition may be maintained in contact with the subject in a manner sufficient to provide a flux which is 0.15 ⁇ g/cm 2 /hr or greater after reaching a peak transdermal flux of 0.5 ⁇ g/cm 2 /hr, such as 0.18 ⁇ g/cm 2 /hr or greater after reaching a peak transdermal flux of 0.6 ⁇ g/cm 2 /hr, such as 0.225 ⁇ g/cm 2 /hr or greater after reaching a peak transdermal flux of 0.75 ⁇ g/cm 2 /hr, such as 0.27 ⁇ g/cm 2 /hr or greater after reaching a peak flux of 0.9 ⁇ g/cm 2 /hr, such as 0.3 ⁇ g/
  • the transdermal composition is maintained in contact with the subject sufficient to provide a steady state average flux of dexmedetomidine to the subject.
  • steady state is used in its conventional sense to mean that the amount of dexmedetomidine released from the transdermal composition maintains a substantially constant average flux of dexmedetomidine.
  • the dexmedetomidine flux from transdermal delivery devices of interest increases or decreases by 30% or less at any time while the transdermal delivery device is maintained in contact with the subject, such as 20% or less, such as 15% or less, such as 12% or less, such as 10% or less, such as 6% or less, such as 5% or less, such as 4% or less, and including 1% or less at any time while the transdermal delivery device is maintained in contact with the subject.
  • the transdermal delivery device is configured to provide a constant flux, such as by introducing a concentration gradient across the skin or mucous membrane or providing an excess in dexmedetomidine dosage amount.
  • dexmedetomidine transdermal compositions of interest may include a dexmedetomidine dosage that is 5% or greater in excess of the normal dosage amount, such as 10% or greater, such as 15% or greater, such as 20% or greater, and including 25% or greater in excess of the normal dosage amount.
  • an upper limit is, in some instances 50% or less in excess, such as 45% or less in excess, such as 25% or less in excess, such as 20% or less in excess and including 10% or less in excess of the normal dosage amount. While dexmedetomidine transdermal compositions of interest may include an excess in order to provide a constant flux, the excess dosage amount is not absorbed as part of the dosage interval.
  • the transdermal dexmedetomidine composition is maintained in a manner sufficient to provide a constant flux, 25% or less of the available dexmedetomidine in the transdermal composition may not be utilized, such as 20% or less, such as 15% or less, such as 10% or less, such as 5% or less and including 1% or less of the available dexmedetomidine in the transdermal composition may not be utilized during the dosage interval.
  • the average cumulative amount of permeated dexmedetomidine increases at a substantially linear rate over the course of the dosage interval (e.g., 7 days or longer).
  • substantially linearly is meant that the cumulative amount of dexmedetomidine released from the transdermal composition increases at a substantially constant rate (i.e., defined by zero-order kinetics).
  • the change in rate of cumulative permeated dexmedetomidine increases or decreases by 10% or less at any given time while maintaining the transdermal composition in contact with the subject, such as 8% or less, such as 7% or less, such as 6% or less, such as 5% or less, such as 3% or less, such as 2.5% or less, such as 2% or less, and including 1% or less at any time while maintaining the dexmedetomidine transdermal composition in contact with the subject.
  • Methods for treating ADHD, anxiety and insomnia in a subject may also include applying a transdermal delivery device containing a dexmedetomidine composition and maintaining the transdermal dexmedetomidine composition in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine to a subject which provides a mean plasma concentration which ranges from 0.01 ng/mL to 0.4 ng/mL over the course of a dosage interval, such as from 0.05 ng/mL to 0.35 ng/mL, such as from 0.15 ng/mL to 0.4 ng/mL, such as from 0.2 ng/mL to 0.35 ng/mL and including from 0.25 ng/mL to 0.3 ng/mL over the course of the dosage interval.
  • the transdermal delivery device may be maintained in contact with the subject in a manner sufficient to provide a mean plasma concentration which ranges from 0.16 ng/mL to 0.36 ng/mL over the course of a dosage interval (e.g., an 8 hour or longer dosage interval).
  • a mean plasma concentration which ranges from 0.16 ng/mL to 0.36 ng/mL over the course of a dosage interval (e.g., an 8 hour or longer dosage interval).
  • methods include maintaining the transdermal delivery device in contact with the subject in a manner sufficient to provide a desired plasma concentration of dexmedetomidine at specific times during treatment.
  • methods may include applying to the subject a transdermal delivery device containing a dexmedetomidine composition and maintaining the transdermal delivery device in contact with a subject in a manner sufficient to achieve a peak plasma concentration of dexmedetomidine in the subject at about 2 hours or later after applying the transdermal delivery device to the subject, such as at about 2.5 hours or later, such as at about 3 hours or later, such as at about 3.5 hours or later, such as at about 4 hours or later, such as at about 4.5 hours or later and including maintaining the transdermal delivery device in contact with a subject in a manner sufficient to achieve a peak plasma concentration of dexmedetomidine in the subject at about 5 hours or later after applying the transdermal delivery device to the subject.
  • a peak plasma concentration of dexmedetomidine in the subject is achieved at about 3 hours or later after applying the transdermal delivery device to the subject. In other embodiments, a peak plasma concentration of dexmedetomidine in the subject is achieved at about 5 hours or later after applying the transdermal delivery device to the subject.
  • methods may also include determining the plasma concentration of dexmedetomidine during treatment.
  • the plasma concentration may be determined using any convenient protocol, such for example by liquid chromatography-mass spectrometry (LCMS).
  • the plasma concentration of the dexmedetomidine may be determined at any time desired.
  • the plasma concentration of dexmedetomidine may be monitored throughout the entire time the transdermal delivery device is maintained in contact with the subject, such by real-time data collection.
  • the plasma concentration of dexmedetomidine is monitored while maintaining the transdermal delivery device in contact with the subject by collecting data at regular intervals, e.g., collecting data every 0.25 hours, every 0.5 hours, every 1 hour including every 2 hours, or some other interval.
  • the plasma concentration of dexmedetomidine is monitored while maintaining the transdermal delivery device in contact with the subject by collecting data according to a particular time schedule after applying the transdermal delivery device to the subject.
  • the plasma concentration of dexmedetomidine may be determined 15 minutes after applying the transdermal delivery device to the subject, 30 minutes after applying the transdermal delivery device to the subject, 1 hour after applying the transdermal delivery device to the subject, 2 hours after applying the transdermal delivery device to the subject and including 3 hours after applying the transdermal delivery device to the subject.
  • the plasma concentration of dexmedetomidine is determined before the transdermal delivery device is applied to a subject, such as for example, to determine the basal plasma concentration of the dexmedetomidine.
  • the plasma concentration may be determined 5 minutes before applying the transdermal delivery device, such as 10 minutes before, such as 30 minutes before, such as 60 minutes before and including 120 minutes before applying the transdermal delivery device.
  • methods may include multiple dosage intervals where applying and maintaining the transdermal delivery device in contact with the subject may be repeated.
  • the plasma concentration may be determined after a first transdermal delivery device is removed and before a second transdermal delivery device is applied.
  • the blood plasma concentration of the dexmedetomidine may be determined one or more times at any given measurement period, such as 2 or more times, such as 3 or more times, including 5 or more times at each measurement period.
  • An upper limit for the number of times the blood plasma concentration of dexmedetomidine is determined at any given measurement period is, in some instances, 10 times or fewer, such as 7 times or fewer, such as 5 times or fewer, such as 3 times or fewer and including 2 times or fewer.
  • the number of times the blood plasma concentration of dexmedetomidine is determined at any given measurement period ranges such as from 2 times to 10 times, such as from 3 times to 9 times, such as from 4 times to 8 times and including from 5 times to 7 times.
  • aspects of the invention include treating ADHD, anxiety or insomnia in a subject by applying a transdermal delivery device containing a dexmedetomidine composition and maintaining the transdermal dexmedetomidine composition in contact with the subject.
  • methods for treating ADHD, anxiety or insomnia in a subject may include maintaining the transdermal composition in contact with the subject in a manner sufficient to deliver a predetermined amount of dexmedetomidine to the subject.
  • the amount of dexmedetomidine in the compositions of interest may range from 0.001 mg to 10 mg, such as 0.005 to 9.5 mg, such as 0.01 mg to 8.5 mg, such as 0.05 to 8 mg, such as 0.1 mg to 7.5 mg, such as 0.5 mg to 7 mg and including from 1 mg to 5 mg.
  • the predetermined amount of dexmedetomidine delivered to the subject may be a percentage of the total amount of dexmedetomidine present in the compositions.
  • the predetermined amount of dexmedetomidine delivered to the subject may be 5% or greater of the total amount of dexmedetomidine present in the composition, such as 10% or greater, such as 25% or greater, such as 40% or greater, such as 45% or greater and including 50% or greater of the total amount of dexmedetomidine present in the composition.
  • an upper limit over the course of a dosage interval is, in some instances, 90% or less, such as 75% or less, such as 50% or less and including 25% or less over the course of a dosage interval.
  • methods may include maintaining the transdermal delivery device in contact with the subject in a manner sufficient to deliver 0.5 mg or more of dexmedetomidine in the transdermal composition over the course of the dosage interval, such as 1.0 mg or more, such as 2.5 mg or more, such as 4.5 mg or more, such as 5.5 mg or more and including maintaining the transdermal delivery device in contact with the subject in a manner sufficient to deliver 5 mg or more of dexmedetomidine in the transdermal composition.
  • the predetermined amount of dexmedetomidine delivered to the subject may be a percentage of the total amount of dexmedetomidine present in the dexmedetomidine transdermal compositions.
  • the predetermined amount of dexmedetomidine delivered to the subject may be 1% or greater of the total amount of dexmedetomidine present in the dexmedetomidine transdermal composition, such as 2% or greater, such as 5% or greater, such as 10% or greater, such as 25% or greater and including 50% or greater of the total amount of dexmedetomidine present in the dexmedetomidine transdermal composition.
  • methods may include maintaining the dexmedetomidine transdermal composition in contact with the subject in a manner sufficient to deliver 5% or greater of the dexmedetomidine in the dexmedetomidine transdermal composition to the subject over the course of a single dosage interval.
  • the utilization percentage of dexmedetomidine is 5% or greater during the time the transdermal delivery device is maintained in contact with the subject. As such, 95% or less of the original amount of dexmedetomidine remains in the dexmedetomidine transdermal composition after a dosage interval.
  • the subject transdermal delivery devices are capable of high utilization percentage.
  • the subject transdermal delivery devices are capable of delivering dexmedetomidine to the subject leaving little residual dexmedetomidine in the transdermal delivery device after a given dosage interval.
  • the utilization percentage may be 5% or greater over the course of a dosage interval, such as 10% or greater, such as 25% or greater, such as 40% or greater, such as 45% or greater and including 50% or greater of the dexmedetomidine over the course of a dosage interval.
  • an upper limit over the course of a dosage interval is, in some instances, 90% or less, such as 50% or less, such as 25% or less and including 5% or less over the course of a dosage interval.
  • methods may include maintaining the transdermal delivery device in contact with the subject in a manner sufficient to deliver 0.05 mg or more of dexmedetomidine in the dexmedetomidine transdermal composition over the course of the dosage interval (e.g., 7 days or longer), such as 0.1 mg or more, such as 0.25 mg or more, such as 0.4 mg or more, such as 0.45 mg or more and including maintaining the transdermal delivery device in contact with the subject in a manner sufficient to deliver 0.5 mg or more of dexmedetomidine in the dexmedetomidine composition.
  • the dosage interval e.g. 7 days or longer
  • 0.95 mg or less of dexmedetomidine remains in the dexmedetomidine transdermal composition after 7 days or longer, such as 0.9 mg or less, such as 0.75 mg or less, such as 0.6 mg or less and including 0.5 mg or less of dexmedetomidine remains in the dexmedetomidine transdermal composition after the dosage interval.
  • transdermal delivery devices include a single layer matrix dexmedetomidine composition which is configured to deliver an amount of dexmedetomidine sufficient to treat ADHD, anxiety or insomnia in a subject.
  • methods according to certain instance include applying a transdermal delivery device having a single layer matrix dexmedetomidine composition and maintaining the single layer dexmedetomidine composition in contact with the subject over a period of time sufficient to deliver an amount of dexmedetomidine sufficient to treat ADHD, anxiety and insomnia in the subject.
  • each of the subject methods described in greater detail below may further include the step of removing the transdermal delivery device from contact with the subject at the conclusion of a dosage interval.
  • the transdermal delivery device may be removed from contact with the subject after maintaining the transdermal delivery device in contact with the subject for 0.5 hours or more, such as 1 hour or more, such as 2 hours or more, such as 4 hours or more, such as 8 hours or more, such as 12 hours or more and including 24 hours or more.
  • An upper limit for the amount of time the transdermal delivery device is maintained in contact with a subject before removal is, in some instances, 24 hours or shorter, such as 20 hours or shorter, such as 16 hours or shorter, such as 12 hours or shorter, such as 8 hours or shorter, such as 4 hours or shorter, such as 3 hours or shorter, such as 2 hours or shorter and including 1 hour or shorter.
  • removing the transdermal delivery device from contact with the subject is meant that no amount of dexmedetomidine from the transdermal composition remains in contact with the subject, including any residual amount of dexmedetomidine left behind on the surface of the skin or mucous membrane when the transdermal delivery device was applied. In other words, when the transdermal delivery device is removed all traces of dexmedetomidine are no longer on the surface of the skin or mucous membrane at the application site, resulting in zero transdermal flux of dexmedetomidine into the subject.
  • a dosage interval is a single administration of applying and maintaining the transdermal delivery device in contact with the subject which begins with applying the transdermal dexmedetomidine composition to the skin or mucous membrane of the subject and ends with the removal of the transdermal delivery device from contact with the subject.
  • protocols for may include multiple dosage intervals.
  • multiple dosage intervals is meant more than one transdermal delivery device is applied and maintained in contact with the subject in a sequential manner. As such, a transdermal delivery device is removed from contact with the subject and a new transdermal delivery device is reapplied to the subject.
  • treatment regimens may include two or more dosage intervals, such as three or more dosage intervals, such as four or more dosage intervals, such as five or more dosage intervals, including ten or more dosage intervals.
  • the location on the subject for reapplying subsequent transdermal delivery devices in multiple dosage treatment regimens may be the same or different from the location on the subject where the previous transdermal delivery device was removed. For example, if a first transdermal delivery device is applied and maintained on the leg of the subject, one or more subsequent transdermal delivery devices may be reapplied to the same position on the leg of the subject. On the other hand, if a first transdermal delivery device was applied and maintained on the leg of the subject, one or more subsequent transdermal delivery device may be reapplied to a different position, such as the abdomen or back of the subject. Subsequent dosages applied in multiple dosage interval regimens may have the same or different formulation of dexmedetomidine.
  • a subsequent dosage interval in a treatment regimen may contain a higher or lower concentration of dexmedetomidine than the previous dosage interval.
  • concentration of dexmedetomidine may be increased in subsequent dosage intervals by 10% or greater, such as 20% or greater, such as 50% or greater, such as 75% or greater, such as 90% or greater and including 100% or greater.
  • An upper limit for the increase in concentration of dexmedetomidine in subsequent dosage intervals is, in some instances, 10-fold or less, such as 5-fold or less, such as 2-fold or less, such as 1-fold or less, such as 0.5-fold or less and including 0.25-fold or less.
  • the concentration of dexmedetomidine may be decreased in subsequent dosage intervals, such as by 10% or greater, such as 20% or greater, such as 50% or greater, such as 75% or greater, such as 90% or greater and including 100% or greater.
  • An upper limit for the decrease in concentration of dexmedetomidine in subsequent dosage intervals is, in some instances, 10-fold or less, such as 5-fold or less, such as 2-fold or less, such as 1-fold or less, such as 0.5-fold or less and including 0.25-fold or less.
  • a subsequent dosage interval may contain a different formulation of dexmedetomidine than the previous dosage interval, such as a different pressure sensitive adhesive or the presence or absence of a permeation enhancer, as described in greater detail below.
  • compositions of the invention can be administered prior to, concurrent with, or subsequent to other therapeutic agents for treating the same or an unrelated condition. If provided at the same time as another therapeutic agent, the subject dexmedetomidine compositions may be administered in the same or in a different composition. Thus, dexmedetomidine compositions of interest and other therapeutic agents can be administered to the subject by way of concurrent therapy.
  • concurrent therapy is intended administration to a subject such that the therapeutic effect of the combination of the substances is caused in the subject undergoing therapy.
  • concurrent therapy may be achieved by administering dexmedetomidine compositions of the invention with a pharmaceutical composition having at least one other agent, such as an analgesic (such as an opioid), anesthetic, antihypertensive, chemotherapeutic, among other types of therapeutics, which in combination make up a therapeutically effective dose, according to a particular dosing regimen.
  • an analgesic such as an opioid
  • anesthetic such as anesthetic
  • antihypertensive chemotherapeutic
  • chemotherapeutic among other types of therapeutics, which in combination make up a therapeutically effective dose, according to a particular dosing regimen.
  • Administration of the separate pharmaceutical compositions can be performed simultaneously or at different times (i.e., sequentially, in either order, on the same day, or on different days), so long as the therapeutic effect of the combination of these substances is caused in the subject undergoing therapy.
  • the weight ratio of dexmedetomidine to second therapeutic agent may range from 1:2 and 1:2.5; 1:2.5 and 1:3; 1:3 and 1:3.5 1:3.5 and 1:4; 1:4 and 1:4.5; 1:4.5 and 1:5; 1:5 and 1:10; and 1:10 and 1:25 or a range thereof.
  • the weight ratio of dexmedetomidine to second therapeutic agent may range between 1:1 and 1:5; 1:5 and 1:10; 1:10 and 1:15; or 1:15 and 1:25.
  • the weight ratio of the second therapeutic agent to dexmedetomidine ranges between 2:1 and 2.5:1; 2.5:1 and 3:1; 3:1 and 3.5:1; 3.5:1 and 4:1; 4:1 and 4.5:1; 4.5:1 and 5:1; 5:1 and 10:1; and 10:1 and 25:1 or a range thereof.
  • the ratio of the second therapeutic agent dexmedetomidine may range between 1:1 and 5:1; 5:1 and 10:1; 10:1 and 15:1; or 15:1 and 25:1.
  • aspects of the invention also include dexmedetomidine transdermal delivery devices for delivering an amount of dexmedetomidine to a subject suitable for practicing the subject methods.
  • Transdermal delivery devices of interest include a composition having dexmedetomidine and a pressure sensitive adhesive.
  • Dexmedetomidine is the S-enantiomer of medetomidine described by the formula:
  • Dexmedetomidine may be in the form of a free base, salt, solvate, hydrate or complex.
  • dexmedetomidine may be in the form of a pharmaceutically acceptable salt including, but not limited to, a mesylate, maleate, fumarate, tartrate, hydrochloride, hydrobromide, esylate, p-toluenesulfonate, benzoate, acetate, phosphate and sulfate salt.
  • Dexmedetomidine according to some embodiments may be a free base. In other instances, dexmedetomidine may form a complex.
  • the amount of dexmedetomidine in compositions of interest may vary, in some instances, the amount of dexmedetomidine ranges from 0.001 mg to 50 mg, such as 0.005 mg to 40 mg, such as 0.01 to 30 mg, such as 0.05 to 20 mg, and including 0.1 mg to 10 mg. In some embodiments, the amount of dexmedetomidine in the transdermal composition ranges from 0.1% to 20% w/w, such as 0.5% to 18% w/w, such as 1% to 15%, such as 2% to 12.5% w/w and including 3% to 10% w/w.
  • the amount of dexmedetomidine in the subject transdermal compositions is 10% by weight or less of the total weight of the transdermal composition, such as 9% by weight or less, such as 8% by weight or less, such as 7% by weight or less, such as 6% by weight or less, such as 5% by weight or less and including 3% by weight or less of the total weight of the transdermal composition.
  • dexmedetomidine compositions include an amount which is below the saturation point of dexmedetomidine.
  • dexmedetomidine compositions include a saturated amount of dexmedetomidine.
  • dexmedetomidine compositions include a supersaturated amount of dexmedetomidine.
  • dexmedetomidine compositions described herein are formulated to deliver a sedative amount of dexmedetomidine.
  • sedative is meant that the dexmedetomidine composition is formulated to deliver an amount of dexmedetomidine to the subject which causes at least partial sedation.
  • transdermal delivery devices include dexmedetomine compositions formulated to deliver an amount of dexmedetomidine to the subject such that the subject is characterized as being in a state where the subject can exhibit brisk response to light glabellar tap or loud auditory stimulus.
  • transdermal delivery devices include dexmedetomine compositions formulated to deliver an amount of dexmedetomidine to the subject such that the subject exhibits a sluggish response to light glabellar tap or loud auditory stimulus.
  • transdermal delivery devices include a dexmedetomidine composition formulated to deliver an amount of dexmedetomidine which is fully sedative and the subject is characterized as being in a state where the subject exhibits no response to touch or auditory stimulus.
  • dexmedetomidine transdermal compositions of interest are formulated such that throughout transdermal administration the subject may be evaluated according to the Ramsey Sedation Scale and assigned a Ramsey score of 2 or higher, such as 3 or higher, such as 4 or higher and including a Ramsey score of 5.
  • methods may include delivering an amount of dexmedetomidine to the subject in manner sufficient to maintain a Ramsay score of between 2 and 5 in the subject, such as between 3 and 5 and including a Ramsay score of between 4 and 5.
  • transdermal dexmedetomidine compositions also include a pressure sensitive adhesive.
  • Pressure sensitive adhesives may include, but are not limited to, poly-isobutene adhesives, poly-isobutylene adhesives, poly-isobutene/polyisobutylene adhesive mixtures, carboxylated polymers, acrylic or acrylate copolymers, such as carboxylated acrylate copolymers.
  • the polybutene may be saturated polybutene.
  • the polybutene may be unsaturated polybutene.
  • the polybutene may be a mixture or combination of saturated polybutene and unsaturated polybutene.
  • the pressure sensitive adhesive may include a composition that is, or is substantially the same as, the composition of Indopol® L-2, Indopol® L-3, Indopol® L-6, Indopol® L-8, Indopol® L-14, Indopol® H-7, Indopol® H-8, Indopol® H-15, Indopol® H-25, Indopol® H-35, Indopol® H-50, Indopol® H-100, Indopol® H-300, Indopol® H-1200, Indopol® H-1500, Indopol® H-1900, Indopol® H-2100, Indopol® H-6000, Indopol® H-18000, Panalane® L-14E, Panalane® H-300E and combinations thereof.
  • the polybutene pressure-sensitive adhesive is Indopol® H-1900. In other embodiments, the polybutene pressure-sensitive adhesive is Panalane® H-300E.
  • Acrylate copolymers of interest include copolymers of various monomers, such as “soft” monomers, “hard” monomers or “functional” monomers.
  • the acrylate copolymers can be composed of a copolymer including bipolymer (i.e., made with two monomers), a terpolymer (i.e., made with three monomers), or a tetrapolymer (i.e., made with four monomers), or copolymers having greater numbers of monomers.
  • the acrylate copolymers may be crosslinked or non-crosslinked.
  • the polymers can be cross-linked by known methods to provide the desired polymers.
  • the monomers from of the acrylate copolymers may include at least two or more exemplary components selected from the group including acrylic acids, alkyl acrylates, methacrylates, copolymerizable secondary monomers or monomers with functional groups.
  • Monomers (“soft” and “hard” monomers) may be methoxyethyl acrylate, ethyl acrylate, butyl acrylate, butyl methacrylate, hexyl acrylate, hexyl methacrylate, 2-ethylbutyl acrylate, 2-ethylbutyl methacrylate, isooctyl acrylate, isooctyl methacrylate, 2-ethylhexyl acrylate, 2-ethylhexyl methacrylate, decyl acrylate, decyl methacrylate, dodecyl acrylate, dodecyl methacrylate, tridecyl acrylate, tridecyl
  • the pressure sensitive adhesive is an acrylate-vinyl acetate copolymer.
  • the pressure sensitive adhesive may include a composition that is, or is substantially the same as, the composition of Duro-Tak® 87-9301, Duro-Tak® 87-200A, Duro-Tak®87-2353, Duro-Tak®87-2100, Duro-Tak®87-2051, Duro-Tak®87-2052, Duro-Tak®87-2194, Duro-Tak®87-2677, Duro-Tak®87-201A, Duro-Tak®87-2979, Duro-Tak®87-2510, Duro-Tak®87-2516, Duro-Tak®87-387, Duro-Tak®87-4287, Duro-Tak®87-2287, and Duro-Tak®87-2074 and combinations thereof.
  • the term “substantially the same” as used herein refers to a composition that is an acrylate-vinyl acetate copolymer in an organic solvent solution.
  • the acrylic pressure-sensitive adhesive is Duro-Tak® 87-2054.
  • the pressure sensitive adhesive is an acrylate adhesive that is a non-functionalized acrylate, hydroxyl-functionalized acrylate or an acid functionalized acrylate.
  • the acrylate adhesive may be an acrylic adhesive having one or more —OH functional groups.
  • the pressure sensitive adhesive may be a composition that is, or is substantially the same as, the composition of Duro-Tak® 87-4287, Duro-Tak® 87-2287, Duro-Tak® 87-2510 and Duro-Tak® 87-2516 and combinations thereof.
  • the acrylate adhesive may alternatively be an acrylic adhesive having one or more —COOH functional groups.
  • the pressure sensitive adhesive may be a composition that is or is substantially the same as, the composition of Duro-Tak® 87-387, Duro-Tak® 87-2979 and Duro-Tak® 87-2353 and combinations thereof. Still further, the acrylate adhesive may be a non-functionalized acrylic adhesive. Where the acrylic adhesive is non-functionalized, in some instances the pressure sensitive adhesive may be a composition that is or is substantially the same as, the composition of Duro-Tak® 87-9301.
  • the amount of pressure sensitive adhesive in transdermal dexmedetomidine compositions of interest may vary, the amount of pressure sensitive adhesive ranging from 0.1 mg to 2000 mg, such as 0.5 mg to 1500 mg, such as 1 to 1000 mg, such as 10 to 750 mg, and including 10 mg to 500 mg. As such, the amount of pressure sensitive adhesive in the transdermal composition ranges from 1% to 99% w/w, such as 5% to 95% w/w, such as 10% to 95%, such as 15% to 90% w/w and including 20% to 85% w/w.
  • the amount of pressure sensitive adhesive in the subject transdermal compositions is 70% by weight or greater of the total weight of the transdermal composition, such as 75% by weight or greater, such as 80% by weight or greater, such as 85% by weight or greater, such as 90% by weight or greater, such as 95% by weight or greater and including 97% by weight or greater of the total weight of the transdermal composition.
  • the weight ratio of pressure sensitive adhesive to dexmedetomidine in the subject compositions may range from 1:2 and 1:2.5; 1:2.5 and 1:3; 1:3 and 1:3.5 1:3.5 and 1:4; 1:4 and 1:4.5; 1:4.5 and 1:5; 1:5 and 1:10; 1:10 and 1:25; 1:25 and 1:50; 1:50 and 1:75; and 1:75 and 1:99 or a range thereof.
  • the weight ratio of pressure sensitive adhesive to dexmedetomidine in compositions of interest may range between 1:1 and 1:5; 1:5 and 1:10; 1:10 and 1:15; 1:15 and 1:25; 1:25 and 1:50; 1:50 and 1:75 or 1:75 and 1:99.
  • the weight ratio of dexmedetomidine to pressure sensitive adhesive in the subject compositions ranges between 2:1 and 2.5:1; 2.5:1 and 3:1; 3:1 and 3.5:1; 3.5:1 and 4:1; 4:1 and 4.5:1; 4.5:1 and 5:1; 5:1 and 10:1; 10:1 and 25:1; 25:1 and 50:1; 50:1 and 75:1; and 75:1 and 99:1 or a range thereof.
  • the ratio of dexmedetomidine to pressure sensitive adhesive in compositions of interest may range between 1:1 and 5:1; 5:1 and 10:1; 10:1 and 15:1; 15:1 and 25:1; 25:1 and 50:1; 50:1 and 75:1; or 75:1 and 99:1.
  • transdermal dexmedetomidine compositions may further include one or more crosslinked hydrophilic polymers.
  • the crosslinked polymer may be an amine-containing hydrophilic polymer.
  • Amine-containing polymers may include, but are not limited to, polyethyleneimine, amine-terminated polyethylene oxide, amine-terminated polyethylene/polypropylene oxide, polymers of dimethyl amino ethyl methacrylate, and copolymers of dimethyl amino ethyl methacrylate and vinyl pyrrolidone.
  • the crosslinked polymer is crosslinked polyvinylpyrrolidone, such as for example PVP-CLM.
  • the matrix may contain other additives depending on the adhesive used.
  • materials such as PVP-CLM, PVP K17, PVP K30, PVP K90, that inhibit drug crystallization, have hygroscopic properties that improve the duration of wear, and improve the physical properties, e.g., cold flow, tack, cohesive strength, of the adhesive.
  • the amount of crosslinked polymer in dexmedetomidine compositions of interest may vary, the amount of crosslinked polymer ranging from 0.1 mg to 500 mg, such as 0.5 mg to 400 mg, such as 1 to 300 mg, such as 10 to 200 mg, and including 10 mg to 100 mg.
  • the amount of crosslinked polymer in the transdermal composition ranges from 2% to 30% w/w, such as 4% to 30% w/w, such as 5% to 25%, such as 6% to 22.5% w/w and including 10% to 20% w/w.
  • the amount of crosslinked polymer in the subject transdermal compositions is 8% by weight or greater of the total weight of the transdermal composition, such as 10% by weight or greater, such as 12% by weight or greater, such as 15% by weight or greater, such as 20% by weight or greater, such as 25% by weight or greater and including 30% by weight crosslinked polymer or greater of the total weight of the transdermal composition.
  • the subject transdermal dexmedetomidine compositions further include a dexmedetomidine solubility enhancer.
  • a dexmedetomidine solubility enhancer is meant a compound or composition which increases the dexmedetomidine solubility in the subject compositions, such as, for example, to prevent any unwanted crystallization of dexmedetomidine in the composition.
  • the dexmedetomidine solubilization enhancer is incorporated into the dexmedetomidine composition in an amount ranging from 0.01% to 20% (w/w), such as from 0.05% to 15% (w/w), such as from 0.1% to 10% (w/w), such as from 0.5% to 8% (w/w) and including from 1% to 5% (w/w).
  • Example solubility enhancers include, but are not limited to acids including linolic acid, oleic acid, linolenic acid, stearic acid, isostearic acid, levulinic acid, palmitic acid, octanoic acid, decanoic acid, dodecanoic acid, tetradecanoic acid, hexadecanoic acid, octadecanoic acid (i.e., stearic acid), N-lauroyl sarcosine, L-pyroglutamic acid, lauric acid, succinic acid, pyruvic acid, glutaric acid, sebacic acid, cyclopentane carboxylic acid; acylated amino acids.
  • acids including linolic acid, oleic acid, linolenic acid, stearic acid, isostearic acid, levulinic acid, palmitic acid, octanoic acid, decanoic acid,
  • solubility enhancers of interest may include, but is not limited to aliphatic alcohols, such as saturated or unsaturated higher alcohols having 12 to 22 carbon atoms (e.g., oleyl alcohol or lauryl alcohol); fatty acid esters, such as isopropyl myristate, diisopropyl adipate, lauryl lactate, propyl laurate, ethyl oleate and isopropyl palmitate; alcohol amines, such as triethanolamine, triethanolamine hydrochloride, and diisopropanolamine; polyhydric alcohol alkyl ethers, such as alkyl ethers of polyhydric alcohols such as glycerol, ethylene glycol, propylene glycol, 1,3-butylene glycol, diglycerol, polyglycerol, diethylene glycol, polyethylene glycol, dipropylene glycol, polypropylene glycol, polypropylene glycolmonolaurate, sorbitan, sorb
  • glycerides i.e., fatty acid esters of glycerol
  • glycerol esters of fatty acids having 6 to 18 carbon atoms where the glycerides may be monoglycerides (i.e., a glycerol molecule covalently bonded to one fatty acid chain through an ester linkage), diglycerides (i.e., a glycerol molecule covalently bonded to two fatty acid chains through ester linkages), triglycerides (i.e., a glycerol molecule covalently bonded to three fatty acid chains through ester linkages), or combinations thereof, where the fatty acid components forming the glycerides include oct
  • solubility enhancers may include lactic acid, tartaric acid, 1,2,6-hexanetriol, benzyl alcohol, lanoline, potassium hydroxide (KOH), tris(hydroxymethyl)aminomethane, glycerol monooleate (GMO), sorbitan monolaurate (SML), sorbitan monooleate (SMO), laureth-4 (LTH), and combinations thereof.
  • the solubility absorption enhancer is levulinic acid, lauryl lactate or propylene glycolmonolaurate.
  • compositions of the invention may vary.
  • compositions of the invention may be in the form of a liquid solution or suspension, syrup, gel, foam or any combination thereof for application by the transdermal delivery device.
  • the transdermal delivery device is configured to include a single layer matrix dexmedetomidine composition.
  • single layer is meant that the transdermal delivery device includes only a single layer of dexmedetomidine composition disposed on the surface of a substrate of the transdermal delivery device and does not include separate distinct layers for the pressure sensitive adhesive, transdermal dexmedetomidine composition, or if present any solubility enhancers.
  • single layer transdermal delivery devices of the present invention do not further include a separate dexmedetomidine reservoir (i.e., active agent reservoir) separate from the pressure sensitive adhesive.
  • single layer transdermal delivery devices of the present invention may include in a single matrix an amount of each of the components of the transdermal dexmedetomidine compositions necessary for practicing the subject methods, as described in greater detail below.
  • single layer transdermal delivery devices of interest include a single layer matrix of dexmedetomidine and a pressure sensitive adhesive which is configured to deliver a an amount of dexmedetomidine sufficient to treat ADHD, anxiety or insomnia in a subject.
  • single layer transdermal delivery devices of interest include a single layer matrix of dexmedetomidine, a pressure sensitive adhesive and a solubility enhancer which is configured to deliver an amount of dexmedetomidine sufficient to treat ADHD, anxiety or insomnia in a subject.
  • single layer transdermal delivery devices of interest include a single layer matrix of dexmedetomidine, a pressure sensitive adhesive and a fatty acid ester which is configured to deliver an amount of dexmedetomidine sufficient to treat ADHD, anxiety or insomnia in a subject.
  • single layer transdermal delivery devices of interest include a single layer matrix having only dexmedetomidine and a pressure sensitive adhesive.
  • the thickness of single layer matrices of interest may vary, in some instances ranging in thickness from 10 to 260 microns, such as 15 to 250 microns, such as 25 to 225 microns, such as 50 to 200 microns, such as 75 to 175 microns and including 20 to 130 microns such as 35 to 110 microns.
  • the size of subject transdermal delivery devices may vary, in some instances sized to cover the entire application site on the subject.
  • the transdermal delivery device may have a length ranging from 1 to 100 cm, such as from 1 to 60 cm and a width ranging from 1 to 100 cm, such as from 1 to 60 cm.
  • the area of the transdermal delivery device may range from 4 cm 2 to 10,000 cm 2 , such as from 5 cm 2 to 1000 cm 2 , such as from 10 cm 2 to 100 cm 2 , such as from 15 cm 2 to 50 cm 2 and including from 20 cm 2 to 40 cm 2 .
  • the transdermal delivery device is sized to have an area of 30 cm 2 .
  • the transdermal delivery device is insoluble in water.
  • insoluble in water is meant that that the transdermal delivery device may be immersed in water for a period of 1 day or longer, such as 1 week or longer, including 1 month or longer, and exhibit little if any dissolution, e.g., no observable dissolution.
  • the transdermal delivery device as described above furthers includes an overlay backing layer.
  • the overlay backing may be flexible, such as so that it can be brought into close contact with the desired application site on the subject.
  • the overlay backing may be fabricated from a material that does not absorb the dexmedetomidine, and does not allow the dexmedetomidine to be leached from the matrix.
  • Overlay backing layers of interest may include, but are not limited to, non-woven fabrics, woven fabrics, films (including sheets), porous bodies, foamed bodies, paper, composite materials obtained by laminating a film on a non-woven fabric or fabric, and combinations thereof.
  • Non-woven fabric may include polyolefin resins such as polyethylene and polypropylene; polyester resins such as polyethylene terephthalate, polybutylene terephthalate and polyethylene naphthalate; rayon, polyamide, poly(ester ether), polyurethane, polyacrylic resins, polyvinyl alcohol, styrene-isoprene-styrene copolymers, and styrene-ethylene-propylene-styrene copolymers; and combinations thereof.
  • Fabrics may include cotton, rayon, polyacrylic resins, polyester resins, polyvinyl alcohol, and combinations thereof.
  • Films may include polyolefin resins such as polyethylene and polypropylene; polyacrylic resins such as polymethyl methacrylate and polyethyl methacrylate; polyester resins such as polyethylene terephthalate, polybutylene terephthalate and polyethylene naphthalate; and besides cellophane, polyvinyl alcohol, ethylene-vinyl alcohol copolymers, polyvinyl chloride, polystyrene, polyurethane, polyacrylonitrile, fluororesins, styrene-isoprene-styrene copolymers, styrene-butadiene rubber, polybutadiene, ethylene-vinyl acetate copolymers, polyamide, and polysulfone; and combinations thereof.
  • Papers may include impregnated paper, coated paper, wood free paper, Kraft paper, Japanese paper, glassine paper, synthetic paper, and combinations thereof.
  • the size of the overlay backing may vary, and in some instances sized to cover the entire application site on the subject.
  • the backing layer may have a length ranging from 2 to 100 cm, such as 4 to 60 cm and a width ranging from 2 to 100 cm, such as 4 to 60 cm.
  • the overlay backing layer may insoluble in water. By insoluble in water is meant that that the backing layer may be immersed in water for a period of 1 day or longer, such as 1 week or longer, including 1 month or longer, and exhibit little if any dissolution, e.g., no observable dissolution.
  • Transdermal delivery devices having a dexmedetomidine composition according to embodiments of the invention are non-irritable to the skin of the subject at the site of application. Irritation of the skin is referred to herein in its general sense to refer to adverse effects, discoloration or damage to the skin, such as for example, redness, pain, swelling or dryness. As such, in practicing methods with the subject transdermal delivery devices the quality of the skin remains normal and transdermal delivery is consistent throughout the entire dosage interval.
  • skin irritation is evaluated to determine the quality and color of the skin at the application site and to determine whether any damage, pain, swelling or dryness has resulted from maintaining the transdermal composition in contact with the subject.
  • the skin may be evaluated for irritation by any convenient protocol, such as for example using the Draize scale, as disclosed in Draize, J. H., Appraisal of the Safety of Chemicals in Foods, Drugs and Cosmetics, pp. 46-49, The Association of Food and Drug Officials of the United States: Austin, Tex., the disclosure of which is herein incorporated by reference.
  • the skin may be evaluated at the transdermal application site for erythema or edema. For example, grades for erythema and edema may be assigned based on visual observation or palpation:
  • the site of application may be evaluated for skin irritation at any time during the subject methods.
  • the skin is evaluated for irritation while maintaining the transdermal delivery device in contact with the subject by observing or palpating the skin at regular intervals, e.g., every 0.25 hours, every 0.5 hours, every 1 hour, every 2 hours, every 4 hours, every 12 hours, every 24 hours, including every 72 hours, or some other interval.
  • the site of application may be evaluated for skin irritation while maintaining the transdermal delivery device in contact with the subject, such as 15 minutes after applying the transdermal delivery device to the subject, 30 minutes after applying the transdermal delivery device, 1 hour after applying the transdermal delivery device, 2 hours after applying the transdermal delivery device, 4 hours after applying the transdermal delivery device, 8 hours after applying the transdermal delivery device, 12 hours after applying the transdermal delivery device, 24 hours after applying the transdermal delivery device, 48 hours after applying the transdermal delivery device, 72 hours after applying the transdermal delivery device, 76 hours after applying the transdermal delivery device, 80 hours after applying the transdermal delivery device, 84 hours after applying the transdermal delivery device, 96 hours after applying the transdermal delivery device, 120 hours after applying the transdermal delivery device, including 168 hours after applying the transdermal delivery device.
  • the site of transdermal application is evaluated for skin irritation after the transdermal delivery device has been removed from contact with the subject.
  • the site of application may be evaluated for skin irritation 30 minutes after removing the transdermal delivery device, such as 1 hour after removing the transdermal delivery device, such as 2 hours after removing the transdermal delivery device, such as 4 hours after removing the transdermal delivery device, such as 8 hours after removing the transdermal delivery device, such as 12 hours after removing the transdermal delivery device, such as 24 hours after removing the transdermal delivery device, such as 48 hours after removing the transdermal delivery device, including 72 hours after removing the transdermal delivery device.
  • the site of transdermal application is evaluated for skin irritation before the transdermal delivery device is applied to a subject, such as to record the skin color and texture before commencing a dosage interval.
  • the site of application may be evaluated for skin irritation 5 minutes before applying the transdermal delivery device, such as 10 minutes, such as 30 minutes, such as 60 minutes, such as 120 minutes, such as 240 minutes and including 480 minutes before applying the transdermal delivery device.
  • the site of application may be evaluated for skin irritation after each transdermal delivery device is removed and before the subsequent transdermal delivery device is applied.
  • the site of application may be evaluated for skin irritation 2 hours, 24 hours and 48 hours after removal and before application of a second transdermal delivery device.
  • a subsequent transdermal delivery device may be applied to the previous site of application immediately after evaluating the skin for irritation or may be applied after a predetermined time after evaluating the skin for irritation, such as 4 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours or 168 hours after evaluating the skin for irritation.
  • the site of application may be evaluated for skin irritation one or more times before, during or after a dosage interval, such as 2 or more times, such as 3 or more times, including 5 or more times before, during or after a dosage interval.
  • An upper limit for the number of times the site of application may be evaluated for skin irritation before, during or after a dosage interval is, in some instances, 10 times or fewer, such as 7 times or fewer, such as 5 times or fewer, such as 3 times or fewer and including 2 times or fewer.
  • the number of times the site of application may be evaluated for skin irritation before, during or after a dosage interval ranges such as from 2 times to 10 times, such as from 3 times to 9 times, such as from 4 times to 8 times and including from 5 times to 7 times.
  • skin irritation may be monitored throughout the entire time the transdermal delivery device is maintained in contact with the subject, such by video monitoring.
  • kits for use in practicing certain methods described herein include one or more transdermal delivery devices containing a dexmedetomidine composition having an amount of dexmedetomidine and pressure sensitive adhesive as described above.
  • the kits include an adhesive overlay as described above.
  • the compositions may be individually packaged or present within a common container.
  • kits will further include instructions for practicing the subject methods or means for obtaining the same (e.g., a website URL directing the user to a webpage which provides the instructions), where these instructions may be printed on a substrate, where substrate may be one or more of: a package insert, the packaging, reagent containers and the like.
  • substrate may be one or more of: a package insert, the packaging, reagent containers and the like.
  • the one or more components are present in the same or different containers, as may be convenient or desirable.
  • Formulations were prepared by mixing dexmedetomidine and a pressure sensitive adhesive in organic solvents (e.g., 30-60 wt % solid content in ethyl acetate, isopropyl alcohol, hexane, or heptane), followed by mixing. Once a homogeneous mixture was formed, the solution was cast on a release liner (siliconized polyester or fluoropolymer coated polyester sheets of 2-3 mils) and dried at 60°-80° C. for 10-90 minutes. The single layer adhesive films were then laminated to a PET backing, cut to the desired size, and pouched.
  • organic solvents e.g., 30-60 wt % solid content in ethyl acetate, isopropyl alcohol, hexane, or heptane
  • crosslinked polyvinylpyrrolidone PVP-CLM
  • polyvinylpyrrolidone K90 PVP K90
  • LA levulinic acid
  • OA oleic acid
  • LL lauryl lactate
  • PGML propylene glycolmonolaurate
  • Pressure-sensitive adhesives used in this example are polyisobutylene/polybutene (PIB/PB) adhesives.
  • the PIB/PB adhesives are mixtures of high molecular weight PIB (5% Oppanol B100), low molecular weight PIB (25% Oppanol B12) and a polybutene tackifier, e.g., Indopol H1900 or Panalane H-300e (20%) in organic solvent, e.g., heptane (50%). The combination was mixed for about 3 days, until the mixture was homogeneous.
  • Example dexmedetomidine transdermal composition formulations are shown in Tables 1 and 2.
  • FIG. 1 An in-vitro skin flux study was performed as described above with transdermal delivery devices having different concentrations of dexmedetomidine as shown in Table 1.
  • the average dexmedetomidine in-vitro skin flux with respect to time is illustrated in FIG. 1 .
  • dexemedetomidine in-vitro skin flux was high in the initial hours in the case of 1% formulation (Formulation 1) as compared to higher drug loading (Formulations 2 and 3).
  • Formulations 2 and 3 were found to have needle-like crystals of dexmedetomidine, therefore flux profile is constant and did not change with drug loading. However, no crystals were observed in Formulation 1.
  • Formulation 1 includes a saturated or supersaturated amount of dexmedetomidine.
  • Dexmedetomidine transdermal formulation was also made using PIB made from Indopol H1900 as shown in Table 2.
  • the results of dexmedetomidine in-vitro permeation from 1% dexmedetomidine formulation made with 20% PVP-CLM in PIB/PB adhesive (Formulation 4) through skins that have different skin permeability are illustrated in FIG. 2 .
  • FIG. 2(A) shows the cumulative dexemedetomidine delivered amount with time.
  • the in-vitro permeation of dexmedetomidine deviated depending on the permeability of the skin.
  • the in-vitro dexmedetomidine delivered amount could vary from 4-35 ug/cm2 at 8 hr.
  • FIG. 2(B) shows the flux or derivative of cumulative drug delivered amount with respect to time.
  • the delivery rate of dexmedetomidine from Formulation 2 reached the maximum at about 5-7 hr, then maintain constant for at least 24 hr. In case of high permeable skin (Skin#14), the flux might decreased due to depletion.
  • FIG. 2(C) shows the % drug remaining in patch with time. As depicted in FIG. 2(C) , the utilization of dexmedetomidine obtained from Formulation 4 was 20-70% after applying the patch for 24 hr.
  • Dexmedetomidine in-vitro flux was measured using non-functionalized acrylate adhesive.
  • An example of a non-functionalized acrylate adhesive used experimentally includes non-functionalized acrylate polymer Duro-Tak 87-9301.
  • An in-vitro skin flux study was performed as described above with transdermal delivery devices having different concentrations of dexmedetomidine in non-functional Duro-Tak 87-9301.
  • Dexmedetomidine transdermal composition formulations are shown in Table 3. The average dexmedetomidine in-vitro flux with respect to time is illustrated in FIG. 3 . As depicted in FIG. 3 , higher dexmedetomidine loading gave increased in-vitro skin flux.
  • Dexmedetomidine in-vitro flux was measured using hydroxyl (—OH) functionalized acrylate adhesives.
  • hydroxyl (—OH) functionalized acrylate adhesives examples include hydroxyl functionalized acrylate polymers, e.g., Duro-Tak 87-4287, Duro-Tak 387/87-2510, Duro-Tak 387/87-2287 and Duro-Tak 387/87-2516.
  • An in-vitro skin flux study was performed as described above with transdermal delivery devices having different concentrations of dexmedetomidine with different hydroxyl functionalized acrylate adhesives.
  • Tables 4 and 5 show the dexmedetomidine transdermal composition formulations with different concentrations of dexmedetomidine in Duro-Tak 87-4287 (acrylate-viny lacetate polymer) or Duro-Tak 387/87-2510 (acrylate polymer).
  • the mean dexmedetomidine in-vitro fluxes are illustrated in FIGS. 4 and 5 . As depicted in FIGS. 4 and 5 , dexmedetomidine in-vitro flux increased with the dexmedetomidine loading in the formulation.
  • Formulation 10 (1% DMT/ (2% DMT/ (3% DMT/ Components DT4287) DT4287) DT4287) Dexmedetomidine 1.00 2.00 3.00 base Pressure Sensitive 99.00 98.00 97.00 Adhesive Duro-Tak 87-4287
  • Tables 6 show the dexmedetomidine transdermal composition formulations containing 1% dexmedetomidine in another hydroxyl functionalized acrylate polymers containing vinyl acetate, e.g., Duro-Tak 87-2287 (no crosslinker added polymer) and Duro-Tak 87-2516 (crosslinker added polymer).
  • the mean dexmedetomidine in-vitro fluxes are illustrated in FIG. 6 . As depicted in FIG.
  • in-vitro flux obtained from Duro-Tak 387/87-2287 was slightly higher than that from Duro-Tak 387/87-2516, possibly resulting from the higher adhesion properties of Duro-Tak 387/87-2287 compared with Duro-Tak 387/87-2516.
  • Formulation 15 Components (1% DMT/DT2287) (1% DMT/DT2516) Dexmedetomidine base 1.00 1.00 Pressure Sensitive 99.00 0.00 Adhesive Duro-Tak 387/87-2287 Pressure Sensitive 0.00 99.00 Adhesive Duro-Tak 387/87-2516
  • transdermal compositions which include 1% w/w dexmedetomidine with non-functionalized acrylate polymer (Duro-Tak 87-9301, Formulation 5), hydroxyl functionalized acrylate polymer (Duro-Tak 387/87-2510, Formulation 11) and hydroxyl functionalized acrylate polymer containing vinyl acetate (Duro-Tak 87-4287, Formulation 8).
  • In-vitro flux experiments were performed for 3 days and 1 day and the results are shown in FIGS. 7A and 7B , respectively. As depicted in both FIGS. 7A and 7B , dexmedetomidine in-vitro flux was less in non-functional adhesives as compared to hydroxyl functionalized adhesives with the same drug loading.
  • Dexmedetomidine in-vitro flux was measured using acid (—COOH) functionalized or acid/hydroxyl (—COOH/OH) functionalized acrylate adhesives.
  • acid (—COOH) functionalized acrylate adhesive used in this study is Duro-Tak 387/87-2353 (no crosslinker added acrylate polymer).
  • the acid/hydroxyl (—COOH/OH) functionalized acrylate adhesive used in this study is Duro-Tak 87-2979 (crosslinker added acrylate-vinyl acetate polymer).
  • Tables 7 and 8 show the dexmedetomidine transdermal composition formulations with different acid (—COOH) functionalized or acid/hydroxyl (—COOH/OH) functionalized acrylate polymers.
  • concentration of dexmedetomidine in the formulations was selected based on the solubility of dexmedetomidine in each adhesive.
  • the solubility of dexmedetomidine in Duro-Tak 387/87-2353 was found to be about 10-15%, whereas that in Duro-Tak 87-2979 was found to be less than 2%.
  • the solubility of drug in acid functionalized acrylate adhesives was greater than that in non-functionalized or hydroxyl functionalized acrylate adhesives.
  • In-vitro skin flux study was performed as described above. The mean dexmedetomidine in-vitro fluxes are illustrated in FIGS. 8 and 9 .
  • dexmedetomidine transdermal composition formulation is shown in Table 9.
  • PIB/PB e.g., Indopol H-1900
  • PVP-CLM acid (—COOH) functionalized acrylate polymer
  • Formulations 18 to 21 were prepared with different loadings of Duro-Tak 387/87-2353.
  • Formulations containing acid (—COOH) functionalized acrylate polymer (Duro-Tak 387/87-2353), Formulations 19, 20 and 21, appear to have lower initial flux compared with Formulations without Duro-Tak 2353 (Formulation 18).
  • the in-vitro flux of dexmedetomidine did not change with 3% and 6% of acid functionalized adhesive, however, at 9% acid functionalized adhesive, a slight decrease in the in-vitro flux is observed.
  • Formulation 19 Formulation 20
  • Formulation 21 Formulation 18 (3% DMT/3% (3% DMT/6% (3% DMT/9% (3% DMT/20% DT2353/18.8% DT2353/18.2% DT2353/17.6% Components CLM/PIB) CLM/PIB) CLM/PIB) CLM/PIB) Dexmedetomidine base 3.00 3.00 3.00 3.00 PVP-CLM 20.00 18.8 18.7 18.6 Pressure Sensitive — 3.00 6.00 9.00 Adhesive Duro-Tak 387/87-2353 PIB/PB (Indopol H-1900) q.s. to 100 q.s. to 100 q.s. to 100 q.s. to 100 q.s. to 100
  • dexmedetomidine transdermal composition formulation is shown in Table 10.
  • PIB/PB e.g., Indopol H-1900
  • PVP-CLM adenosine-maleic anhydride
  • in-vitro flux of dexmedetomidine was reduced dramatically where the formulation included 6.9% of levulinic acid.
  • in-vitro flux was comparable to lower concentrations of levulinic acid (i.e., 0.6% and 0.9%).
  • the initial flux obtained from formulations containing levulenic acid (Formulations 22,23,24 and 25) was lower than that from formulation without levulinic acid (Formulation 18)
  • the flux obtained from the formulations containing levulenic acid (Formulations 22,23,24 and 25) appear to be higher than that from formulation without levulinic acid (Formulation 17).
  • Dexmedetomidine crystals were observed at levulinic acid concentrations of 1.75% and lower.
  • dexmedetomidine transdermal composition formulations are shown in Tables 11 and 12.
  • Dexmedetomidine has solubility of 5 to 10% in lauryl lactate and propylene glycolmonolaurate.
  • lauryl lactate and propylene glycolmonolaurate increase solubility of dexmedetomidine in the PIB/PB adhesive in the subject formulations.
  • In-vitro flux profiles of Formulations 26 to 28 are shown in FIG. 12 .
  • In-vitro flux profiles of Formulations 29 to 31 are shown in FIG. 13 .
  • Formulations 26 to 31 were found to have needle-like crystals of dexmedetomidine,
  • Formulation 27 (3% DMT/3% (3% DMT/6% (3% DMT/9% LL/20% LL/20% LL/20% Components CLM/PIB) CLM/PIB) CLM/PIB) Dexmedetomidine 3.00 3.00 3.00 base PVP-CLM 20.00 20.00 20.00 Lauryl lactate 3.0 6.0 9.0 PIB/PB (Indopol q.s. to 100 q.s. to 100 q.s. to 100 H-1900)
  • Formulation 31 (3% DMT/4% (3% DMT/8% (3% DMT/12% PGML/20% PGML/20% PGML/20% Components CLM/PIB) CLM/PIB) CLM/PIB) Dexmedetomidine 3.00 3.00 3.00 base PVP-CLM 20.00 20.00 20.00 Propylene 4.0 8.0 12.0 glycolmonolaurate PIB/PB (Indopol q.s. to 100 q.s. to 100 q.s.to 100 H-1900)
  • dexmedetomidine transdermal formulation include transdermal compositions having 1% w/w dexmedetomidine with a solubilizer to improve physical stability of the composition.
  • levulinic acid, PVP K90 and Duro-Tak 87-2353 were employed.
  • the formulation compositions are shown in Tables 13, 14 and 15.
  • In-vitro flux profiles for transdermal compositions having 1% dexmedetomidine with 0.3% and 0.6% levulinic acid are shown in FIG. 14(A) .
  • In-vitro flux profiles for transdermal compositions having 1% dexmedetomidine with 5% and 10% PVP K90 are shown in FIG. 14(B) .
  • In-vitro flux profiles for transdermal compositions having 1% dexmedetomidine with 2% or 3% Duro-Tak 387/87-2353 are shown in FIG. 14(C) . From the in-vitro flux profiles, levulinic acid enhanced the permeation after application for 15 hr., PVP K90 delayed transdermal flux of dexmedetomidine whereas Duro-Tak 2353 slightly reduced transdermal flux.
  • dexmedetomidine transdermal formulation include transdermal compositions having 3% w/w dexmedetomidine and non-functionalized acrylate polymer Duro-Tak 87-9301 in combination with 3.3% levulinic acid, 5% Oleic acid or 15% Duro-Tak 387/87-2353.
  • the formulation compositions are shown in Table 16.
  • In-vitro flux profiles for these formulations (Formulations 38,39 and 40), compared with 3% dexmedetomidine in non-functionalized acrylate polymer Duro-Tak 87-9301 without additive (Formulation 7) are illustrated in FIG. 15 .
  • compositions having just 3% dexmedetomidine and non-functionalized acrylate polymer Duro-Tak 87-9301 were supersaturated.
  • Levulinic acid and oleic acid were used as a solubilizer and permeation enhancer and increased flux at the beginning of in-vitro flux, but declined with time.
  • Duro-Tak 87-2353 reduced flux.
  • Formulation 40 (3% DMT/ (3% DMT/ (3% DMT/ 3.3% LA/ 5% OA/ 15% DT2353/ Components DT9301) DT9301) DT9301) Dexmedetomidine 3.00 3.00 3.00 base Levulinic acid 3.30 0.00 0.00 Oleic acid 0.00 5.00 0.00 Pressure Sensitive 0.00 0.00 15.00 Adhesive Duro-Tak 387/87-2353 Pressure Sensitive 93.70 92.00 82.00 Adhesive Duro-Tak 87-9301
  • Dexmedetomidine transdermal composition formulations containing the mixture of hydroxyl functionalized acrylate polymer (e.g., Duro-Tak 87-2287) and acid functionalized acrylate polymer (e.g., Duro-Tak 87-2353) are summarized in Table 17.
  • Formulations 41 to 44 were prepared with different loadings of dexmedetomidine.
  • in-vitro flux of dexmedetomidine increased with increasing percent of dexmedetomidine loading.
  • dexmedetomidine transdermal composition formulations is summarized in Table 18.
  • oleic acid was used in order to increase the solubility of dexmedetomidine in the hydroxyl functionalized acrylate polymer (e.g., Duro-Tak 87-2287).
  • Formulations 45 to 47 were prepared with different loadings of oleic acid and dexmedetomidine.
  • dexmedetomidine in formulations containing oleic acid has a higher flux than a dexmedetomidine composition (e.g., Formulation 43) which does not contain oleic acid.
  • Oleic acid enhanced the permeation of dexmedetomidine through the skin.
  • An increase of oleic acid from 5% to 7% did not show an enhancement effect as compared to the formulation containing 5% oleic acid (e.g. Formulation 45). This may be the result of the contribution of oleic acid in increasing in solubility of dexmedetomidine in the composition.
  • a comparison of Formulation 45 and Formulation 47 shows that the in-vitro flux increases with increasing percent drug loading.
  • Dexmedetomidine transdermal formulations were also prepared with levulinic acid. The composition is shown in Table 19.
  • in-vitro flux of dexmedetomidine in formulations containing levulinic acid increased with percent dexmedetomidine loading.
  • the enhancement effect of levulinic acid on permeation of dexmedetomidine through the skin was higher than oleic acid.
  • the solubility of dexmedetomidine in hydroxyl functionalized acrylate polymer was less than 1%.
  • an acid functionalized acrylate polymer e.g., Duro-Tak2353
  • oleic acid and levulinic acid were used.
  • the solubility of dexmedetomidine in Duro-Tak2353, oleic acid and levulinic acid was about 10-15%, 40% and 60% respectively.
  • the amount of acid added in the formulation was adjusted according to the solubility of each component in the formulation.
  • PIB/PB adhesives Polyisobutylene/Polybutene (PIB/PB) adhesives.
  • the PIB/PB adhesives are mixtures of high molecular weight PIB (5% Oppanol B100), low molecular weight PIB (25% Oppanol B12) and a polybutene tackifier, e.g., Indopol H1900 or Panalane H-300e (20%), in an organic solvent, e.g., heptane (50%). The combination was mixed for about 3 days, until the mixture was homogeneous.
  • Example dexmedetomidine transdermal composition formulations are shown in Table 21.
  • backing 1 has a MVTR value (g/m 2 /24 hr) around 10
  • Backing 2 has a MVTR value around 50 (g/m 2 /24 hr)
  • backing 3 has MVTR value around 150 (g/m 2 /24 hr).
  • dexmedetomidine in-vitro skin flux The average dexmedetomidine in-vitro skin flux with respect to time is illustrated in FIG. 19 . As depicted in FIG. 19 , dexmedetomidine in-vitro skin flux was similar for backing 1 and 2. But it is significantly lower with backing 3.
  • dexmedetomidine transdermal formulation examples include transdermal compositions having 2-4% w/w dexmedetomidine with an enhancer to improve skin permeability.
  • lauryl lactate (LL) and Duro-Tak 87-2287 were employed.
  • the formulation compositions are shown in Table 22.
  • FIGS. 20 and 21 show the flux on two different skin samples. From the in-vitro flux profiles, LL shows its skin permeability enhancement effect. The flux is also proportional to API loading.
  • the flux profile of all formulations showed a clear increasing trend in flux with time during the first 24 hours ( FIGS. 16 to 18 ). This is followed by a gradual decrease in flux with time. As such, the increase in flux during the first 24 hours may, in certain instances, be useful for achieving a rapid higher initial therapeutic concentration in the body. Where there is a decrease in flux with time, the decrease in flux could be due to the crystallization of the drug in the adhesive induced by the absorbed water in the patch.
US14/505,933 2013-10-07 2014-10-03 Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions Abandoned US20150098997A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/505,933 US20150098997A1 (en) 2013-10-07 2014-10-03 Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions
US16/587,995 US10874642B2 (en) 2013-10-07 2019-09-30 Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361887862P 2013-10-07 2013-10-07
US14/505,933 US20150098997A1 (en) 2013-10-07 2014-10-03 Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/587,995 Continuation US10874642B2 (en) 2013-10-07 2019-09-30 Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions

Publications (1)

Publication Number Publication Date
US20150098997A1 true US20150098997A1 (en) 2015-04-09

Family

ID=52777135

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/505,933 Abandoned US20150098997A1 (en) 2013-10-07 2014-10-03 Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions
US16/587,995 Active US10874642B2 (en) 2013-10-07 2019-09-30 Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/587,995 Active US10874642B2 (en) 2013-10-07 2019-09-30 Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions

Country Status (10)

Country Link
US (2) US20150098997A1 (zh)
EP (1) EP3054935B1 (zh)
JP (2) JP6310070B2 (zh)
KR (1) KR101831290B1 (zh)
CN (1) CN106456561B (zh)
CA (1) CA2924233C (zh)
ES (1) ES2856189T3 (zh)
RU (1) RU2658463C2 (zh)
TW (2) TWI629066B (zh)
WO (1) WO2015054059A2 (zh)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170239221A1 (en) * 2014-10-15 2017-08-24 Bioxcel Corporation Prevention or treatment of sleep disorders using dexmedetomidine formulation
WO2020006092A1 (en) 2018-06-27 2020-01-02 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
CN111346072A (zh) * 2018-12-21 2020-06-30 宜昌人福药业有限责任公司 一种透皮给药的药物组合物及其制备方法
EP3839959A1 (en) * 2019-12-19 2021-06-23 Koninklijke Philips N.V. Transdermal sedative release control in autonomous imaging
US11786508B2 (en) 2016-12-31 2023-10-17 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11890272B2 (en) 2019-07-19 2024-02-06 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
EP4108237A4 (en) * 2020-02-19 2024-03-06 Nitto Denko Corp TRANSDERMAL PATCH

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101831290B1 (ko) * 2013-10-07 2018-02-22 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 조성물을 사용하여 주의력 결핍 과잉행동 장애, 불안 및 불면증을 치료하기 위한 방법 및 조성물
US9974754B2 (en) 2013-12-18 2018-05-22 Maruishi Pharmaceutical Co., Ltd. Hydrous adhesive patch
US20150195549A1 (en) * 2014-01-08 2015-07-09 Qualcomm Incorporated Support of non-hevc base layer in hevc multi-layer extensions
KR102577838B1 (ko) * 2020-10-29 2023-09-12 히사미쓰 세이야꾸 가부시키가이샤 로피니롤 함유 첩부제 및 로피니롤의 피부 투과성 향상 방법

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817332A (en) * 1994-07-08 1998-10-06 Urtti; Arto O. Transdermal drug delivery system
US20020102291A1 (en) * 1997-12-15 2002-08-01 Noven Pharmaceuticals, Inc. Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US6689379B1 (en) * 1999-04-22 2004-02-10 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with neutralized acrylic adhesive patch
US20090098191A1 (en) * 2007-10-16 2009-04-16 Anderson Christopher G Use of bases to stabilize transdermal formulations
WO2011085162A2 (en) * 2010-01-08 2011-07-14 Recro Pharma, Inc. Topical transdermal dexmedetomidine compositions and methods of use thereof
US20130331803A1 (en) * 2010-11-17 2013-12-12 Hexal Ag Transdermal therapeutic system comprising buprenorphine

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
JPS60163811A (ja) 1984-02-06 1985-08-26 Watanabe Yakuhin Kogyo Kk プロプラノロ−ル含有外用貼付剤
FI844786A0 (fi) 1984-12-04 1984-12-04 Farmos Oy Terapeutiskt utnyttjbar foerening.
FI864570A0 (fi) * 1986-11-11 1986-11-11 Farmos Oy Terapeutiskt anvaendbar foerening.
GB2206880B (en) 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
GB2215206B (en) 1988-02-29 1991-07-03 Farmos Oy 4-substituted imidazole derivatives useful in perioperative care
US4994267A (en) 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5217718A (en) 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
US5304569A (en) 1989-11-13 1994-04-19 Orion-Yhtyma Oy Compositions and their use in lowering intraocular pressure
US5070084A (en) 1990-02-26 1991-12-03 Campbell James N Treatment of sympathetically maintained pain
US5447947A (en) 1990-02-26 1995-09-05 Arc 1 Compositions and methods of treatment of sympathetically maintained pain
JP2849937B2 (ja) 1990-04-18 1999-01-27 日東電工株式会社 医療用貼付剤
GB9111732D0 (en) 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
WO1993007842A1 (en) * 1991-10-15 1993-04-29 Cygnus Therapeutic Systems Thermal enhancement of transdermal drug administration
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
GB2281206A (en) 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
JPH0776526A (ja) 1993-09-06 1995-03-20 Sansei Seiyaku Kk 乳酸エステルを含有する経皮吸収製剤
JP4102901B2 (ja) 1994-09-14 2008-06-18 スリーエム カンパニー 経皮薬剤導入用マトリックス
US5635203A (en) 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
WO2000023066A2 (en) 1998-10-20 2000-04-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
WO1996030416A1 (fr) 1995-03-31 1996-10-03 Sekisui Kagaku Kogyo Kabushiki Kaisha Procede de preparation d'adhesifs acryliques du genre solvant, sensibles a la pression, et adhesif medical sensible a la pression
PL181582B1 (pl) 1995-06-07 2001-08-31 Ortho Mcneil Pharm Inc Plaster na skóre do zapobiegania owulacji u kobiety oraz plaster na skóre do przeprowadzania hormonalnej terapii substytucyjnej PL PL PL PL PL PL PL PL
US5891461A (en) 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
GB9521680D0 (en) 1995-10-23 1996-01-03 Orion Yhtymo Oy New use of imidazole derivatives
US7150881B2 (en) * 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
EP1021204B1 (en) 1997-09-26 2005-12-28 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US20020016319A1 (en) 1998-02-25 2002-02-07 Olney John W. Combined adamantane derivative and adrenergic agonist for relief of chronic pain without adverse side effects
US20020068754A1 (en) 1998-02-25 2002-06-06 Olney John W. Combination of adrenergic agonist and aryl-cyclo-alkanolamine for relieving chronic pain without adverse side effects
US20020177592A1 (en) 1998-02-25 2002-11-28 Olney John W. Combination of adrenergic agonist and tricyclo-alkylamine for relieving chronic pain without adverse side effects
AR015744A1 (es) 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
JP2002526403A (ja) 1998-10-02 2002-08-20 スリーエム イノベイティブ プロパティズ カンパニー 粘膜を起点としたデリバリーシステムおよび動物への適用
US20030170195A1 (en) 2000-01-10 2003-09-11 Noven Pharmaceuticals, Inc. Compositions and methods for drug delivery
PE20001396A1 (es) 1999-01-18 2000-12-23 Gruenenthal Chemie Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
GB9913677D0 (en) 1999-06-11 1999-08-11 Imperial College Formulation
DE19938823A1 (de) 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
WO2001047512A2 (en) 1999-12-08 2001-07-05 Fluoro Probe, Inc. Method for relieving pain associated with an internal disease site
AU7576501A (en) 2000-03-28 2001-12-03 John W. Olney Combination of adrenergic agonist and nmda antagonist for relieving chronic painwithout adverse side effects
US20050042194A1 (en) 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
US7635488B2 (en) 2001-03-13 2009-12-22 Dbv Technologies Patches and uses thereof
FR2832311B1 (fr) 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
AR033748A1 (es) 2002-05-15 2004-01-07 Thalas Group Inc Un dispositivo para la administracion transdermica de sustancias farmacologicamente activas que comprende dos capas adhesivas superpuestas y un procedimiento para prepararlo
KR100511492B1 (ko) 2002-10-11 2005-08-31 주식회사 태평양 에페리손, 톨페리손 또는 그것들의 염을 포함하는경피흡수제제
KR20050111317A (ko) 2003-01-23 2005-11-24 샤이어 홀딩스 아게 혈소판혈병의 치료를 위한 제형 및 방법
DE10305137A1 (de) 2003-02-07 2004-08-26 Novosis Ag Transdermale therapeutische Abgabesysteme mit einem Butenolid
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050059664A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Novel methods for identifying improved, non-sedating alpha-2 agonists
US20050020600A1 (en) 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
JP4694967B2 (ja) 2003-07-31 2011-06-08 久光製薬株式会社 貼付剤
US20050058696A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
KR20060126448A (ko) 2003-09-12 2006-12-07 알러간, 인코포레이티드 통증 및 다른 알파 2 아드레날린 매개 증상을 치료하기위한 방법 및 조성물
UA84303C2 (ru) 2003-10-28 2008-10-10 Новен Фармасьютикалз, Инк. Система для трансдермальной доставки лечебного средства
DK1761266T3 (da) 2004-05-25 2013-08-05 Galderma Pharma Sa Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme
CA2580694A1 (en) 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20060166901A1 (en) 2005-01-03 2006-07-27 Yu Ruey J Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids
US20060210613A1 (en) 2005-03-15 2006-09-21 Carliss Richard D Therapeutic wound care product
EP2308480B1 (en) 2005-09-23 2014-08-13 ALZA Corporation High Enhancer-Loading Polyacrylate Formulation for Transdermal Applications
US20070134310A1 (en) 2005-09-23 2007-06-14 Nedberge Diane E Transdermal risperidone delivery system
US20070093555A1 (en) 2005-10-24 2007-04-26 Jutaro Shudo Topical pain relief compositions of N,2,3-trimethyl-2-isopropylbutamide and methods for using the same
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
CN1994290B (zh) 2006-01-04 2011-03-16 上海医药工业研究院 卡巴拉汀透皮贴剂及其制备方法
AU2007204755A1 (en) 2006-01-10 2007-07-19 Eugene J. Van Scott N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use
AU2007209380B2 (en) 2006-01-27 2011-12-08 F. Hoffmann-La Roche Ag Use of 4-imidazole derivatives for CNS disorders
WO2007100775A2 (en) 2006-02-27 2007-09-07 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
WO2007103687A2 (en) 2006-03-01 2007-09-13 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
GB0611241D0 (en) 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
JP4148988B2 (ja) 2006-09-11 2008-09-10 積水化学工業株式会社 貼付剤
SI2818184T1 (sl) 2007-11-16 2019-03-29 Aclaris Therapeutics, Inc. Sestava in postopki za zdravljenje purpure
WO2009124755A1 (en) 2008-04-08 2009-10-15 European Molecular Biology Laboratory (Embl) Compounds with novel medical uses and method of identifying such compounds
JP5547065B2 (ja) 2008-05-15 2014-07-09 久光製薬株式会社 パロノセトロンを含有する経皮吸収製剤
JP2011529490A (ja) 2008-07-28 2011-12-08 エンドジェンエックス， インコーポレイテッド アルファ−２アドレナリン受容体アゴニスト、および、エンドセリン受容体アンタゴニストを用いて疼痛を治療する方法
US20110257188A1 (en) 2008-08-01 2011-10-20 Gerald Horn Compositions and methods for the treatment of nasal conditions
US20110244058A1 (en) 2008-08-01 2011-10-06 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US20100197694A1 (en) 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US20120156244A1 (en) 2008-08-01 2012-06-21 Alpha Synergy Development Inc. Nasal Compositions and Uses Thereof
US20100202979A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
EP2165706A1 (en) 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
US9308203B2 (en) 2008-10-01 2016-04-12 Taiwan Biotech Co., Ltd. Pressure sensitive adhesive matrix device or system for the treatment or prevention of onychomycosis or tinea pedis
WO2010050211A1 (ja) 2008-10-30 2010-05-06 国立大学法人 岡山大学 局所麻酔用組成物
US20120095104A1 (en) 2008-11-30 2012-04-19 Oron Zachar Use of vasoconstrictors
CN102300566A (zh) 2008-11-30 2011-12-28 O·扎查尔 血管收缩剂的皮肤应用
EP2370136A4 (en) 2008-12-01 2015-12-30 Map Pharmaceuticals Inc INHALATIVE RELEASE PROCEDURES AND DEVICES
FR2942138A1 (fr) 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
JP2012158521A (ja) 2009-04-17 2012-08-23 Kureha Corp 外用剤
US20110021588A1 (en) 2009-05-15 2011-01-27 Recro Pharma, Inc. Sublingual dexmeditomidine compositions and methods of use thereof
US8410140B2 (en) 2009-06-01 2013-04-02 The Regents Of The University Of Michigan Anesthetic methods and compositions
WO2011070069A1 (en) 2009-12-09 2011-06-16 I-Tech Ab Process for preparation of medetomidine
US9327105B2 (en) 2010-03-26 2016-05-03 Itrace Biomedical Inc. Active transdermal drug delivery system and the method thereof
WO2011127586A1 (en) 2010-04-15 2011-10-20 The Royal Institution For The Advancement Of Learning / Mcgill University Topical treatments for pain
US9023788B2 (en) 2010-04-20 2015-05-05 New York University Methods compounds and pharmaceutical compositions for treating anxiety and mood disorders
TWI433904B (zh) 2011-01-12 2014-04-11 Taiwan Biotech Co Ltd 多奈哌齊經皮貼片
US20120202864A1 (en) 2011-02-03 2012-08-09 Alpha Synergy Development Inc. Compositions and Methods for Treatment of Glaucoma
US20120309720A1 (en) 2011-02-03 2012-12-06 Alpha Synergy Development Inc. Compositions and methods for treatment of glaucoma
WO2012129429A2 (en) * 2011-03-24 2012-09-27 Teikoku Pharma Usa, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
US20140037710A1 (en) 2011-04-18 2014-02-06 Hisamitsu Pharmaceutical Co., Inc. Method for producing patch, and patch
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
KR20140091544A (ko) 2011-10-19 2014-07-21 갈데르마 소시에떼아노님 모세혈관종 치료방법
WO2013072763A2 (en) 2011-11-16 2013-05-23 Nometics Inc. Non-sensitizing transdermal clonidine patch
PE20142314A1 (es) 2011-12-11 2015-01-23 Recro Pharma Inc Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
WO2013113690A1 (en) 2012-01-31 2013-08-08 Grünenthal GmbH Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine
WO2013173317A1 (en) 2012-05-14 2013-11-21 Prospire, Llc TREATMENT OF OBSTRUCTIVE SLEEP APNEA WITH α2-ADRENERGIC RECEPTOR AGONISTS
ES2651688T3 (es) 2012-08-31 2018-01-29 Pharmazz, Inc. Métodos y composiciones para la reanimación hipotensiva
EP2919814A1 (en) 2012-11-13 2015-09-23 UCL Business Plc. Adrenergic agonists for use in treating liver damage
CA2924188C (en) 2013-10-07 2018-12-18 Teikoku Pharma Usa, Inc. Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions
TWI704933B (zh) 2013-10-07 2020-09-21 美商帝國製藥美國股份有限公司 右美托咪啶經皮輸送裝置及使用其之方法
CA2924190C (en) * 2013-10-07 2019-07-09 Teikoku Pharma Usa, Inc. Methods and compositions for treating withdrawal syndromes using non-sedative dexmedetomidine transdermal compositions
ES2847936T3 (es) * 2013-10-07 2021-08-04 Teikoku Pharma Usa Inc Métodos y composiciones para el suministro transdérmico de una cantidad no sedante de dexmedetomidina
KR101831290B1 (ko) * 2013-10-07 2018-02-22 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 조성물을 사용하여 주의력 결핍 과잉행동 장애, 불안 및 불면증을 치료하기 위한 방법 및 조성물
US9974754B2 (en) 2013-12-18 2018-05-22 Maruishi Pharmaceutical Co., Ltd. Hydrous adhesive patch
WO2016105449A1 (en) 2014-12-22 2016-06-30 Seth Lederman Compounds for use as pain therapeutics

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817332A (en) * 1994-07-08 1998-10-06 Urtti; Arto O. Transdermal drug delivery system
US20020102291A1 (en) * 1997-12-15 2002-08-01 Noven Pharmaceuticals, Inc. Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US6689379B1 (en) * 1999-04-22 2004-02-10 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with neutralized acrylic adhesive patch
US20090098191A1 (en) * 2007-10-16 2009-04-16 Anderson Christopher G Use of bases to stabilize transdermal formulations
WO2011085162A2 (en) * 2010-01-08 2011-07-14 Recro Pharma, Inc. Topical transdermal dexmedetomidine compositions and methods of use thereof
US20130331803A1 (en) * 2010-11-17 2013-12-12 Hexal Ag Transdermal therapeutic system comprising buprenorphine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ebert et al. (Anesthesiology, 2000;93(2):382-94) *
Owens (J Can Acad Child Adolsec Psychiatry 2009;18(2):92-102) *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170239221A1 (en) * 2014-10-15 2017-08-24 Bioxcel Corporation Prevention or treatment of sleep disorders using dexmedetomidine formulation
US11786508B2 (en) 2016-12-31 2023-10-17 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
US11931340B2 (en) 2016-12-31 2024-03-19 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
US11839604B2 (en) 2016-12-31 2023-12-12 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
US11806429B2 (en) 2018-06-27 2023-11-07 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
US11478422B2 (en) 2018-06-27 2022-10-25 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
US11497711B2 (en) 2018-06-27 2022-11-15 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
US11517524B2 (en) 2018-06-27 2022-12-06 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
US11559484B2 (en) 2018-06-27 2023-01-24 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
US10792246B2 (en) 2018-06-27 2020-10-06 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
WO2020006092A1 (en) 2018-06-27 2020-01-02 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
CN111346072A (zh) * 2018-12-21 2020-06-30 宜昌人福药业有限责任公司 一种透皮给药的药物组合物及其制备方法
US11890272B2 (en) 2019-07-19 2024-02-06 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
WO2021122681A1 (en) * 2019-12-19 2021-06-24 Koninklijke Philips N.V. Transdermal sedative release control in autonomous imaging
EP3839959A1 (en) * 2019-12-19 2021-06-23 Koninklijke Philips N.V. Transdermal sedative release control in autonomous imaging
EP4108237A4 (en) * 2020-02-19 2024-03-06 Nitto Denko Corp TRANSDERMAL PATCH
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Also Published As

Publication number Publication date
JP2016532641A (ja) 2016-10-20
TW201517937A (zh) 2015-05-16
JP6310070B2 (ja) 2018-04-11
TWI709417B (zh) 2020-11-11
RU2016109634A (ru) 2017-11-16
WO2015054059A2 (en) 2015-04-16
EP3054935A4 (en) 2017-04-05
CA2924233A1 (en) 2015-04-16
JP2018087209A (ja) 2018-06-07
US10874642B2 (en) 2020-12-29
CN106456561A (zh) 2017-02-22
CN106456561B (zh) 2020-02-28
JP6494818B2 (ja) 2019-04-03
RU2658463C2 (ru) 2018-06-21
CA2924233C (en) 2018-10-23
ES2856189T3 (es) 2021-09-27
TW201900156A (zh) 2019-01-01
BR112016006971A2 (pt) 2017-08-01
EP3054935A2 (en) 2016-08-17
KR101831290B1 (ko) 2018-02-22
KR20160058956A (ko) 2016-05-25
EP3054935B1 (en) 2020-12-09
TWI629066B (zh) 2018-07-11
US20200093800A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
US10874642B2 (en) Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
US10772871B2 (en) Dexmedetomidine transdermal delivery devices and methods for using the same
EP3054931B1 (en) Transdermal delivery device for managing pain comprising dexmedetomidine transdermal compositions
US10987342B2 (en) Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
JP6208859B6 (ja) デクスメデトミジン経皮送達デバイス及びその使用法
BR112016006971B1 (pt) Uso de dispositivo de distribuição transdérmica no tratamento de transtorno de déficit de atenção e hiperatividade (tdah), ansiedade ou insônia

Legal Events

Date Code Title Description
AS Assignment

Owner name: TEIKOKU PHARMA USA, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PONGPEERAPAT, ADCHARA;JAIN, AMIT;BERNER, BRET;AND OTHERS;SIGNING DATES FROM 20141010 TO 20141029;REEL/FRAME:034121/0096

STCV Information on status: appeal procedure

Free format text: ON APPEAL -- AWAITING DECISION BY THE BOARD OF APPEALS

STCV Information on status: appeal procedure

Free format text: BOARD OF APPEALS DECISION RENDERED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION